WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
2.CLM..USPT,PGPB.	7
(L2.CLM.).USPT,PGPB.	7

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L3

Refine Search | Recall Text | Clear

Search History

DATE: Monday, October 28, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L3	L2.clm.	7	L3
L2	(candida) same (vaccin$)	252	L2
L1	pascual-david$	0	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 20020102273 A1

L3: Entry 1 of 7 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102273
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102273 A1

TITLE: USE OF ALPHAVIRUS .EXPRESSION VECTORS TO PRODUCE PARASITE ANITGENS

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
GRIEVE, ROBERT B.	WINDSOR	CO	US	
XIONG, CHENG	FORT COLLINS	CO	US	

US-CL-CURRENT: 424/199.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20020058293 A1

L3: Entry 2 of 7 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058293
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058293 A1

TITLE: Fungal antigens and process for producing the same

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Takesako, Kazutoh	Otsu-shi		JP	
Mizutani, Shigetoshi	Gamo-gun		JP	
Endo, Masahiro	Kusatsu-shi		JP	
Kato, Ikunoshin	Uji-shi		JP	

US-CL-CURRENT: 435/7.31; 424/185.1, 435/183, 435/254.1, 435/320.1, 435/69.3, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 20020054886 A1

L3: Entry 3 of 7 File: PGPB May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020054886
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020054886 A1

TITLE: Candida albicans phosphomannan complex as a vaccine

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cutler, Jim E.	Bozeman	MT	US	
Han, Yongmoon	Bozeman	MT	US	

US-CL-CURRENT: 424/234.1; 536/22.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 6440423 B1

L3: Entry 4 of 7 File: USPT Aug 27, 2002

US-PAT-NO: 6440423
DOCUMENT-IDENTIFIER: US 6440423 B1

TITLE: Mutant enterotoxin effective as a non-toxic oral adjuvant

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Clements; John D.	New Orleans	LA		
Dickinson; Bonny L.	New Orleans	LA		

US-CL-CURRENT: 424/236.1; 424/184.1, 424/200.1, 424/234.1, 424/235.1, 424/240.1, 424/241.1, 424/257.1, 424/261.1, 424/278.1, 424/282.1, 514/2, 530/350, 530/820, 530/825

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 6333164 B1

L3: Entry 5 of 7 File: USPT Dec 25, 2001

US-PAT-NO: 6333164
DOCUMENT-IDENTIFIER: US 6333164 B1

TITLE: Fungal antigens and process for producing the same

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Takesako; Kazutoh	Otsu			JP
Mizutani; Shigetoshi	Gamo-gun			JP
Endo; Masahiro	Kusatsu			JP
Kato; Ikunoshin	Uji			JP

US-CL-CURRENT: 435/7.3; 424/184.1, 424/274.1, 435/174, 435/177, 435/7.2, 435/921, 435/922, 530/350, 530/395, 530/397, 530/399, 530/402, 530/405, 530/406, 530/408, 530/410

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 6290950 B1

L3: Entry 6 of 7 File: USPT Sep 18, 2001

US-PAT-NO: 6290950
DOCUMENT-IDENTIFIER: US 6290950 B1

TITLE: Mycosis vaccines

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Poliakov; Igor Dimitrievich	D-88471 Laupheim			DE
Ivanova; Ludmilla	D-88471 Laupheim			DE

US-CL-CURRENT: 424/93.5; 424/274.1, 424/93.51, 435/254.1, 435/254.2, 435/254.22, 435/255.1, 435/255.7, 435/7.31

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 6033673 A

L3: Entry 7 of 7 File: USPT Mar 7, 2000

US-PAT-NO: 6033673
DOCUMENT-IDENTIFIER: US 6033673 A

TITLE: Double mutant enterotoxin for use as an adjuvant

DATE-ISSUED: March 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Clements; John D.	New Orleans	LA		

US-CL-CURRENT: 424/236.1; 424/184.1, 424/241.1, 424/278.1, 424/282.1, 424/832, 424/9.2, 514/885

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

```
? s s6 and py<1997
Processing
              60  S6
        40195427  PY<1997
     S13      48  S6 AND PY<1997
? rd s13
...completed examining records
     S14      48  RD S13 (unique items)
? ds

Set     Items   Description
S1         76   E1-E4
S2          2   S1 AND (ADHESIN? OR MIMIC?)
S3          2   RD S2 (unique items)
S4          0   S1 AND CANDIDA
S5        114   (CANDIDA)(20N)(PHOSPHOMANN?)
S6         60   RD S5 (unique items)
S7        211   (CANDIDA)(20N)(ADHESIN?)
S8        112   RD S7 (unique items)
S9          9   S8 AND VACCIN?
S10         9   RD S9 (unique items)
S11         6   S6 AND VACCIN?
S12         6   RD S11 (unique items)
S13        48   S6 AND PY<1997
S14        48   RD S13 (unique items)
?
```

```
s (candida)(20n)(adhesin?)
          120770  CANDIDA
           11820  ADHESIN?
      S7     211  (CANDIDA)(20N)(ADHESIN?)
? rd s7
...examined 50 records  (50)
...examined 50 records  (100)
...examined 50 records  (150)
...examined 50 records  (200)
...completed examining records
      S8     112  RD S7 (unique items)
? s s8 and vaccin?
             112  S8
          382239  VACCIN?
      S9       9  S8 AND VACCIN?
? rd s9
...completed examining records
     S10       9  RD S9 (unique items)
? t s10/3all
>>>"3ALL" is not a valid format name in file(s): 5, 73, 155, 399
? t s10/3/all

 10/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11167018   BIOSIS NO.: 199799788163
Biochemical characterization of Candida albicans epitopes that can elicit
  protective and nonprotective antibodies.
AUTHOR: Han Yongmoon; Kanbe Toshio; Cherniak Robert; Cutler Jim E(a)
AUTHOR ADDRESS: (a)Montana State Univ., Dep. Microbiol., Lewis Hall 109,
  Bozeman, MT 59717**USA
JOURNAL: Infection and Immunity  65 (10):p4100-4107 1997
ISSN: 0019-9567
RECORD TYPE: Abstract
LANGUAGE: English


 10/3/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

09921743   BIOSIS NO.: 199598376661
Antibody response that protects against disseminated candidiasis.
AUTHOR: Han Yongmoon; Cutler Jim E(a)
AUTHOR ADDRESS: (a)Montana State Univ., Dep. Microbiol., Lewis Hall 109,
  Bozeman, MT 59717**USA
JOURNAL: Infection and Immunity  63 (7):p2714-2719 1995
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 10/3/3     (Item 1 from file: 73)
DIALOG(R)File  73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

07143748     EMBASE No: 1998031628
  Serologic response to cell wall mannoproteins and proteins of Candida
albicans
  Martinez J.P.; Gil M.L.; Lopez-Ribot J.L.; LaJean Chaffin W.
  J.P. Martinez, Departamento Microbiologia Ecologia, Facultad de Farmacia,
  Universitat de Valencia, Avda. Vicente Andres Estelles s-n,
```

46100-Burjasot, Valencia Spain
AUTHOR EMAIL: jose.pedro.martinez@uv.es
Clinical Microbiology Reviews (CLIN. MICROBIOL. REV.) (United States) 1998, 11/1 (121-141)
CODEN: CMIRE ISSN: 0893-8512
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 318

10/3/4 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137246520 CA: 137(17)246520g PATENT
M cell directed vaccines
INVENTOR(AUTHOR): Pasual, David W.
LOCATION: USA
ASSIGNEE: Research & Development Institute, Inc.
PATENT: PCT International ; WO 200272015 A2 DATE: 20020919
APPLICATION: WO 2002US7254 (20020312) *US PV274639 (20010312)
PAGES: 102 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

10/3/5 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137092728 CA: 137(7)92728s PATENT
Prophylactic and therapeutic immunogenic complex
INVENTOR(AUTHOR): Timmerman, Benedikt
LOCATION: Fr.
PATENT: PCT International ; WO 200253178 A2 DATE: 20020711
APPLICATION: WO 2002IB739 (20020104) *GB 2001757 (20010106)
PAGES: 57 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/02A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

10/3/6 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137077880 CA: 137(6)77880s PATENT
Ribosomal complexes with microbial polynucleotides for mucosal vaccination
INVENTOR(AUTHOR): Timmerman, Benedikt
LOCATION: Fr.

PATENT: PCT International ; WO 200253189 A2 DATE: 20020711
APPLICATION: WO 2002IB738 (20020104) *GB 2001758 (20010106)
PAGES: 61 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-047/48A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

10/3/7 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129053350 CA: 129(5)53350c PATENT
Peptides which mimic Candida carbohydrate epitopes and their use in a vaccine
INVENTOR(AUTHOR): Cutler, Jim E.; Han, Yongmoon; Glee, Pati
LOCATION: USA
ASSIGNEE: Research and Development Institute, Inc.; Cutler, Jim E.; Han, Yongmoon; Glee, Pati
PATENT: PCT International ; WO 9823287 A1 DATE: 19980604
APPLICATION: WO 97US21661 (19971125) *US 756014 (19961125) *US 45030 (19970428)
PAGES: 119 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A; A61K-038/00B; A61K-049/00B; A61K-047/36B; A61K-047/42B; A01N-037/18B; C07K-005/00B; C07K-014/00B DESIGNATED COUNTRIES: AU; CA; JP; US
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

10/3/8 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126046312 CA: 126(4)46312b PATENT
Candida albicans phosphomannoprotein adhesion molecule as vaccine
INVENTOR(AUTHOR): Cutler, Jim E.; Han, Yongmoon
LOCATION: USA
ASSIGNEE: Research and Development Institute, Inc.
PATENT: United States ; US 5578309 A DATE: 19961126
APPLICATION: US 483558 (19950607) *US 247972 (19940523)
PAGES: 30 pp. Cont.-in-part of U.S. Ser. No. 247,972. CODEN: USXXAM
LANGUAGE: English CLASS: 424274100; A61K-039/00A

10/3/9 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

124127108 CA: 124(10)127108a PATENT
Candida albicans adhesin as a vaccine
INVENTOR(AUTHOR): Cutler, Jim E.; Han, Yongmoon
LOCATION: USA
ASSIGNEE: Research and Development Institute, Inc.
PATENT: PCT International ; WO 9531998 A1 DATE: 951130
APPLICATION: WO 95US6832 (950523) *US 247972 (940523)
PAGES: 68 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A; A61K-039/395B; A61K-009/127B; A61K-031/715B; A61K-031/66B; C07K-016/14B; C07K-014/40B; C07H-003/06B; C07H-011/04B DESIGNATED COUNTRIES: AU; CA; JP

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
? t s10/7/1,2

10/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11167018 BIOSIS NO.: 199799788163
Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies.
AUTHOR: Han Yongmoon; Kanbe Toshio; Cherniak Robert; Cutler Jim E(a)
AUTHOR ADDRESS: (a)Montana State Univ., Dep. Microbiol., Lewis Hall 109, Bozeman, MT 59717**USA
JOURNAL: Infection and Immunity 65 (10):p4100-4107 1997
ISSN: 0019-9567
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We previously reported that the immunoglobulin M (IgM) monoclonal antibody (MAb) B6.1 protects mice against disseminated candidiasis, whereas the IgM MAb B6 does not. Both MAbs are specific for an **adhesin** fraction isolated from the cell surface of **Candida** albicans, but their epitope specificities differ. In the present study, we examined the surface locations of both epitopes and obtained structural information regarding the B6.1 epitope. Immunofluorescence confocal microscopic analysis of C. albicans yeast forms showed that epitope B6.1 is displayed rather homogeneously over the entire cell surface, whereas epitope B6 appears to have a patchy distribution. Both antibodies were essentially nonreactive with the surfaces of mycelial forms of the fungus, indicating that neither epitope is expressed on the surfaces of these forms. For isolation of the B6.1 epitope, the adhesin fraction consisting of cell surface phosphomannan was subjected to mildly acidic (10 mM HCl) hydrolysis and was fractionated into acid-labile and acid-stable portions by size exclusion chromatography. Antibody blocking experiments showed that the B6.1 epitope is an acid-labile moiety of the phosphomannan and that the B6 epitope is located in the acid-stable fraction. The B6 epitope appeared to be mannan because it was stable to heat (boiling) and protease treatments but was destroyed by alpha-mannosidase digestion. The B6.1 epitope eluted from the size exclusion column in two fractions. Mass spectroscopic analyses showed that one fraction contained material with the size of a mannotriose and that the other was a mixture of mannotriose- and mannotetraose-size substances. Dose response inhibition tests of the fractions indicated that the B6.1 epitope is associated with the mannotriose. Nuclear magnetic resonance (NMR) spectroscopic analysis of the epitope yielded data consistent with a beta-(1 fwdarw 2)-linked mannotriose. The fine structure of the B6 epitope is under investigation. Information derived from these investigations will be useful both in understanding protective versus nonprotective antibody responses to C. albicans and in improving anti-Candida **vaccine** formulations.

10/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09921743 BIOSIS NO.: 199598376661
Antibody response that protects against disseminated candidiasis.
AUTHOR: Han Yongmoon; Cutler Jim E(a)
AUTHOR ADDRESS: (a)Montana State Univ., Dep. Microbiol., Lewis Hall 109, Bozeman, MT 59717**USA
JOURNAL: Infection and Immunity 63 (7):p2714-2719 1995
ISSN: 0019-9567

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We previously showed that surface mannans of **Candida** albicans function as **adhesins** during yeast cell attachment to mouse splenic marginal zone macrophages. The mannan **adhesin** fraction was encapsulated into liposomes and used to **vaccinate** mice over a 5- to 6-week period. Circulating agglutinins specific for the fraction correlated with increased resistance to disseminated candidiasis. Antiserum from **vaccinated** animals protected naive BALB/cByJ mice against C. albicans serotype A and B strains and Candida tropicalis. Antiserum also protected SCID mice against disseminated disease. The serum protective ability was stable at 56 degree C, but this ability was adsorbed by C. albicans cells. The antiserum was divided into three fractions after separation by high-performance liquid chromatography. One fraction contained all of the agglutinin activity and transferred resistance to naive mice. A second fraction also transferred resistance. Two monoclonal antibodies (MAbs) specific for candidal surface determinants were obtained. MAb B6.1 is specific for a mannan epitope in the adhesin fraction, and MAb B6 is specific for a different epitope in the fraction. Both MAbs are immunoglobulin M, and both strongly agglutinate candidal cells, but only MAb B6.1 protected both normal and SCID mice against disseminated candidiasis. In one experiment, 10 normal mice were given MAb B6.1 and challenged with yeast cells. Six mice survived the 67-day observation period; 4 of the survivors were cured as evidenced by the lack of CFU in the kidney and spleen. Our studies show that antibodies against certain cell surface antigens of C. albicans help the host resist disseminated candidiasis.
? ds

Set	Items	Description
S1	76	E1-E4
S2	2	S1 AND (ADHESIN? OR MIMIC?)
S3	2	RD S2 (unique items)
S4	0	S1 AND CANDIDA
S5	114	(CANDIDA)(20N)(PHOSPHOMANN?)
S6	60	RD S5 (unique items)
S7	211	(CANDIDA)(20N)(ADHESIN?)
S8	112	RD S7 (unique items)
S9	9	S8 AND VACCIN?
S10	9	RD S9 (unique items)

```
? s s6 and vaccin?
            60  S6
        382239  VACCIN?
    S11       6  S6 AND VACCIN?
? rd s11
...completed examining records
    S12       6  RD S11 (unique items)
? t s12/7/all

 12/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14073111   BIOSIS NO.: 200300067140
Candida albicans phosphomannan complex as a vaccine.
AUTHOR: Cutler Jim E; Han Yongmoon
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents  1265 (1):pNo Pagination Dec. 3 2002 2002
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
```

LANGUAGE: English

ABSTRACT: A composition, pharmaceutical composition, **vaccine** and method for the treatment of disseminated candidiasis due to the infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.

12/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13760416 BIOSIS NO.: 200200389237
Peptides which mimic candida carbohydrate epitopes and their use in a **vaccine**.
AUTHOR: Cutler Jim E(a); Han Yongmoon
AUTHOR ADDRESS: (a)Bozeman, MT**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1259 (2):pNo Pagination June 11, 2002
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: A composition, pharmaceutical composition, **vaccine** and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of **phosphomannan** epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against **candida** infections are also provided.

12/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13423836 BIOSIS NO.: 200200052657
Candida albicans **phosphomannoprotein** adhesion as a **vaccine**
AUTHOR: Cutler J E; Han Y
AUTHOR ADDRESS: Bozeman, Mont.**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1192 (4):p2800 Nov. 26, 1996
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Citation
LANGUAGE: English

12/7/4 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09143550 20444422 PMID: 10986077
Synthesis of a beta1,2-mannopyranosyl tetrasaccharide found in the **phosphomannan** antigen of **Candida** albicans.
Nitz M; Purse B W; Bundle D R
Department of Chemistry, University of Alberta, Edmonton, AB, Canada T6G 2G2.
Organic letters (UNITED STATES) Sep 21 2000, 2 (19) p2939-42, ISSN 1523-7060 Journal Code: 100890393
Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

The synthesis of a portion of the challenging beta1,2-mannosyl polymer found in the cell walls of Candida albicans was undertaken to develop a conjugate **vaccine** against C. albicans and to facilitate NMR conformational studies of this unique polysaccharide. The novel approach to the synthesis of tetrasaccharide 1 employed the modified ulosyl bromide 11 as the glycosyl donor which provided high diastereoselectivity. A participating solvent as well as p-chlorobenzyl protection facilitated the new approach.

Record Date Created: 20001011
Record Date Completed: 20001102

12/7/5 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08621505 95310032 PMID: 7790089

Antibody response that protects against disseminated candidiasis.

Han Y; Cutler J E
Department of Microbiology, Montana State University, Bozeman 59717, USA.

Infection and immunity (UNITED STATES) Jul 1995, 63 (7) p2714-9,
ISSN 0019-9567 Journal Code: 0246127
Contract/Grant No.: 1 PO1 AI37194; AI; NIAID; 5 RO1 AI24912; AI; NIAID
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

We previously showed that surface mannans of Candida albicans function as adhesins during yeast cell attachment to mouse splenic marginal zone macrophages. The mannan adhesin fraction was encapsulated into liposomes and used to **vaccinate** mice over a 5- to 6-week period. Circulating agglutinins specific for the fraction correlated with increased resistance to disseminated candidiasis. Antiserum from **vaccinated** animals protected naive BALB/cByJ mice against C. albicans serotype A and B strains and Candida tropicalis. Antiserum also protected SCID mice against disseminated disease. The serum protective ability was stable at 56 degrees C, but this ability was adsorbed by C. albicans cells. The antiserum was divided into three fractions after separation by high-performance liquid chromatography. One fraction contained all of the agglutinin activity and transferred resistance to naive mice. A second fraction also transferred resistance. Two monoclonal antibodies (MAbs) specific for candidal surface determinants were obtained. MAb B6.1 is specific for a mannan epitope in the adhesin fraction, and MAb B6 is specific for a different epitope in the fraction. Both MAbs are immunoglobulin M, and both strongly agglutinate candidal cells, but only MAb B6.1 protected both normal and SCID mice against disseminated candidiasis. In one experiment, 10 normal mice were given MAb B6.1 and challenged with yeast cells. Six mice survived the 67-day observation period; 4 of the survivors were cured as evidenced by the lack of CFU in the kidney and spleen. Our studies show that antibodies against certain cell surface antigens of C. albicans help the host resist disseminated candidiasis.

Record Date Created: 19950727
Record Date Completed: 19950727

12/7/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126046312 CA: 126(4)46312b PATENT

Candida albicans phosphomannoprotein adhesion molecule as vaccine

INVENTOR(AUTHOR): Cutler, Jim E.; Han, Yongmoon
LOCATION: USA
ASSIGNEE: Research and Development Institute, Inc.
PATENT: United States ; US 5578309 A DATE: 19961126
APPLICATION: US 483558 (19950607) *US 247972 (19940523)
PAGES: 30 pp. Cont.-in-part of U.S. Ser. No. 247,972. CODEN: USXXAM
LANGUAGE: English CLASS: 424274100; A61K-039/00A
SECTION:
CA215002 Immunochemistry
CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: Candida albicans phosphomannoprotein adhesin vaccine candidiasis
DESCRIPTORS:
Hypercholesterolemia...
alimentary; cholesterol and lipid metab. in offspring of rabbits with moderate alimentary hypercholesterolemia
Monoclonal antibodies...
anti-Candida albicans; Candida albicans phosphomannoprotein adhesion mol. as vaccine
Adhesins... Candida albicans... Candidiasis... Cell adhesion molecules...
Liposomes...
Candida albicans phosphomannoprotein adhesion mol. as vaccine
Vaccines...
candidiasis; Candida albicans phosphomannoprotein adhesion mol. as vaccine
Candida albicans...
disseminated candidiasis from; Candida albicans phosphomannoprotein adhesion mol. as vaccine
Phosphatidylcholines,biological studies...
liposome contg.; Candida albicans phosphomannoprotein adhesion mol. as vaccine
Glycophosphoproteins...
mannose-contg.; Candida albicans phosphomannoprotein adhesion mol. as vaccine
CAS REGISTRY NUMBERS:
57-88-5 biological studies, liposome contg.; Candida albicans phosphomannoprotein adhesion mol. as vaccine
?

```
begin 5,73,155,399
       30jun03 16:26:28 User208760 Session D2322.2
            $0.00    0.071 DialUnits File410
     $0.00  Estimated cost File410
     $0.01  TELNET
     $0.01  Estimated cost this search
     $0.28  Estimated total session cost   0.148 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R)  1969-2003/Jun W4
         (c) 2003 BIOSIS
  File  73:EMBASE  1974-2003/Jun W4
         (c) 2003 Elsevier Science B.V.
*File  73: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File 155:MEDLINE(R)  1966-2003/Jun W4
         (c) format only 2003 The Dialog Corp.
*File 155: Medline has been reloaded and accession numbers have
changed.  Please see HELP NEWS 155.
  File 399:CA SEARCH(R)  1967-2003/UD=13901
         (c) 2003 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

      Set  Items  Description
      ---  -----  -----------
? e au=pascual david ?

Ref   Items  Index-term
E1       42  AU=PASCUAL D.W.
E2        3  AU=PASCUAL DAVID
E3        0 *AU=PASCUAL DAVID ?
E4       31  AU=PASCUAL DAVID W
E5        1  AU=PASCUAL DE ANDRES T.
E6        8  AU=PASCUAL DE BAZAN H E
E7        2  AU=PASCUAL DE BAZAN H.E.
E8        1  AU=PASCUAL DE BAZAN, H. E.
E9        7  AU=PASCUAL DE BAZAN, HAYDEE E.
E10       1  AU=PASCUAL DE GRADO L
E11       1  AU=PASCUAL DE LA TORRE M
E12       2  AU=PASCUAL DE PABLO E

          Enter P or PAGE for more
? s e1-e4
              42  AU=PASCUAL D.W.
               3  AU=PASCUAL DAVID
               0  AU=PASCUAL DAVID ?
              31  AU=PASCUAL DAVID W
      S1      76  E1-E4
? s s1 and (adhesin? or mimic?)
              76  S1
           11820  ADHESIN?
          153002  MIMIC?
      S2       2  S1 AND (ADHESIN? OR MIMIC?)
? rd s2
...completed examining records
      S3       2  RD S2 (unique items)
? t s3/3/all

 3/3/1     (Item 1 from file: 73)
DIALOG(R)File  73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

10586981     EMBASE No: 2000052345
```

Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigma1
Wu Y.; Boysun M.J.; Csencsits K.L.; **Pascual D.W.**
D.W. Pascual, Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717-3610 United States
Gene Therapy (GENE THER.) (United Kingdom) 2000, 7/1 (61-69)
CODEN: GETHE ISSN: 0969-7128
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 49

3/3/2 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10133779 22112873 PMID: 12117936
Fimbriated Salmonella enterica serovar typhimurium abates initial inflammatory responses by macrophages.
Pascual David W; Trunkle Theresa; Sura Jamie
Veterinary Molecular Biology, Montana State University, Bozeman 59717-3610, USA. dpascual@montana.edu
Infection and immunity (United States) Aug 2002, 70 (8) p4273-81, ISSN 0019-9567 Journal Code: 0246127
Contract/Grant No.: AI41123; AI; NIAID
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

```
? s s1 and candida
              76  S1
          120770  CANDIDA
      S4       0  S1 AND CANDIDA
? s (candida)(20n)(phosphomann?)
          120770  CANDIDA
            2011  PHOSPHOMANN?
      S5     114  (CANDIDA)(20N)(PHOSPHOMANN?)
? rd s5
...examined 50 records  (50)
...examined 50 records  (100)
...completed examining records
      S6      60  RD S5 (unique items)
? t s6/3/all
```

4/7/14 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

06605480 EMBASE No: 1996270243

The effects of administration of anti-**ICAM**-1 and/or anti-LFA-1 monoclonal antibodies on experimental **candida** peritonitis in mice

Maejima T.
Department of Pathology, Shinshu University, School of Medicine,Matsumoto Japan

Shinshu Medical Journal (SHINSHU MED. J.) (Japan) 1996, 44/2 (113-122)
CODEN: SIZAA ISSN: 0037-3826
DOCUMENT TYPE: Journal; Article
LANGUAGE: JAPANESE SUMMARY LANGUAGE: ENGLISH

This study was undertaken to investigate the effects on infectious disease of monoclonal antibodies against adhesion molecules. BALB/c male mice were intravenously administered rat anti-mouse **ICAM**-1 antibody and/or LFA-1 antibody before intraperitoneal inoculation of viable **Candida** albicans cells. Control mice were intravenously administered rat IgG before the inoculation. In control mice, suppurative lesions were observed in peritoneal adipose tissues surrounding the pancreas. The mice given anti-LFA-1 antibody revealed the same circumscribed peritonitis as control mice, while the mice that received anti-**ICAM**-1 antibody developed suppurative lesions in the kidneys in addition to circumscribed peritonitis. In mice administered with both anti-**ICAM**-1 and LFA-1 antibodies, fungal invasion spread into the pancreas and kidneys from the peritoneum, but no leukocyte infiltration was observed. These results suggest that the therapeutic use of anti-adhesion molecule antibodies for various diseases may enhance incidental infections.

4/7/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09796826 BIOSIS NO.: 199598251744
Host defenses against **Candida** are impaired in **ICAM**-1 deficient mice.
AUTHOR: Davis Susan L(a); Hawkins Edith P; Mason Edward O Jr; Smith C Wayne ; Kaplan Sheldon L
AUTHOR ADDRESS: (a)Dep. Pediatr., Baylor Coll. Med., Houston, TX**USA
JOURNAL: Pediatric Research 37 (4 PART 2):p173A 1994
CONFERENCE/MEETING: 105th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the Society for Pediatric Research San Diego, California, USA May 7-11, 1995
ISSN: 0031-3998
RECORD TYPE: Citation

09952381 BIOSIS NO.: 199598407299
Antigen-presenting function of human peritoneum mesothelial cells.
AUTHOR: Valle M T(a); Degl'innocenti M L; Bertelli R; Facchetti P; Perfumo F; Fenoglio D; Kunkl A; Gusmano R; Manca F
AUTHOR ADDRESS: (a)Dep. Immunol., San Martino Hosp., Viale Benedetto XV, 10, 16132 Genoa**Italy
JOURNAL: Clinical and Experimental Immunology 101 (1):p172-176 1995
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Mesothelial cells (MC) from human peritoneal omentum fragments obtained during surgical insertion of peritoneal catheters for continuous peritoneal dialysis in end stage renal failure (ESRF) patients were cultured in vitro. MC exhibited a phenotype different from macrophages, but MHC class II molecules were well expressed. Therefore MC lines were tested for antigen-presenting capacity by pulsing with soluble antigens (tetanus toxoid and purified protein derivative (PPD)) or with a corpusculate antigen (**Candida** albicans bodies). Autologous peripheral blood mononuclear cells (PBMC) depleted of adherent monocytes and cloned T cells generated from an individual matched for the MHC class II antigen DR2 were used to test antigen-presenting function. MC effectively presented the soluble and corpusculate antigens to autologous and MHC-compatible allogeneic lymphocytes, indicating that they are endowed with both endocytic/phagocytic activity and with processing/presenting capacity. Preincubation of MC with human recombinant interferon-gamma (IFN-gamma) up-regulated MHC class II and intercellular adhesion molecule-1 (**ICAM**-1) expression, but the effect on antigen-presenting function was not consistent. Since MC are an important component of the peritoneal environment, they may participate, along with macrophages, in activation of specific T cells and in the

10014682 BIOSIS NO.: 199598469600
Reduced antigen-presenting function of human Epstein-Barr virus (EBV)-B cells and monocytes after UVB radiation is accompanied by decreased expression of B7, intercellular adhesion molecule-1 (**ICAM**-1) and LFA-3.
AUTHOR: Kremer I B(a); Bos J D; Teunissen M B M
AUTHOR ADDRESS: (a)Dep. Dermatol., Room K2-210, Acad. Med. Cent., Univ. Amsterdam, PO Box 22700, 100 DE Amsterdam**Netherlands
JOURNAL: Clinical and Experimental Immunology 101 (3):p461-467 1995
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: In this study, the effect of ultraviolet-B (UVB) radiation on antigen-presenting function was studied, to investigate whether antigen-presenting cells (APC) are inhibited by UVB through a common mechanism. Two types of human APC were used: EBV-B cells and monocytes, and these were irradiated in vitro with single low doses of UVB (range 0-200 J/m-2). Irradiation of EBV-B cells or monocytes resulted in similar dose-dependent reduction in APC function, when determined by the allogeneic mixed leucocyte reaction (MLR) or **Candida** albicans or tetanus toxoid-specific T cell response. Our study shows that the reduced APC function was not likely to be caused by alterations in antigen processing or cytokine production. However, UVB-irradiated APC displayed marked changes in adhesion molecule expression. Irradiated EBV-B cells showed reduced expression of **ICAM**-1 (30%), LFA-3 (25%) and B7-1 (35%), while expression of HLA-DR, CD19 and LFA-1 was not affected. UVB irradiation of monocytes did result in reduction in the expression of HLA-DR (30%), LFA-3 (40%), **ICAM**-1 (65%) and B7-1 and B7-3 (90%), but had no effect on CD14, LFA-1 and **ICAM**-3 expression. Addition of non-irradiated cells (but not the supernatant of these cells) or CD28 antibodies partly restored T cell activation, indicating that UVB-induced reduction in APC function is at least partly mediated via impairment of

4/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10532702 BIOSIS NO.: 199699153847
Host defenses against disseminated candidiasis are impaired in intercellular adhesion molecule 1-deficient mice.
AUTHOR: Davis Susan L(a); Hawkins Edith P; Mason Edward O Jr; Smith C Wayne ; Kaplan Sheldon L
AUTHOR ADDRESS: (a)Texas Children's Hosp., 6621 Fannin, MC 2-3450, Houston, TX 77030**USA
JOURNAL: Journal of Infectious Diseases 174 (2):p435-439 1996
ISSN: 0022-1899
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Genetically engineered mice, which lack normal expression of intercellular adhesion molecule 1 (**ICAM**-1), were used to study the role of **ICAM**-1 in the host defense against disseminated candidiasis. The responses of **ICAM**-1-deficient mice and normal wild type mice were compared following an intravenous challenge with **Candida** albicans. **ICAM**-1-deficient mice lost more weight (P lt .001) and had a significantly higher mortality (P lt .001). Quantitative cultures revealed a greater tissue fungal burden in **ICAM**-1-deficient mice compared with normal mice, in both the kidney (P lt .001) and the brain (P = .007). Extensive inflammation, composed primarily of histiocytes admixed with lymphocytes and occasional neutrophils, was present in the renal tissue of **ICAM**-1-deficient mice; this contrasted with a more localized and predominantly neutrophilic infiltrate in normal mice. This work suggests that the loss of **ICAM**-1 significantly impairs host defense against C. albicans,

7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10800158 BIOSIS NO.: 199799421303
Increased soluble **ICAM**-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease.
AUTHOR: Pirisi M(a); Vitulli D; Falleti E; Fabris C; Soardo G; Del Forno M; Bardus P; Gonano F; Bartoli E
AUTHOR ADDRESS: (a)Cattedra di Medicina Interna, Univ. degli Studi, Piazzale Santa Maria della Misericordia 1, 3310**Italy
JOURNAL: Journal of Clinical Pathology (London) 50 (1):p50-53 1997
ISSN: 0021-9746
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Aims/background-Soluble **ICAM**-1 may act as an antagonist of the membrane bound form, which is essential for the adhesion of leucocytes to endothelial cells. The aim of this study was to investigate whether the presence of high concentrations of soluble **ICAM**-1 are related to the impairment of delayed-type hypersensitivity reactions. Methods-The study population comprised 73 patients (53 men and 20 women) with chronic liver disease (19 with chronic hepatitis, 36 with cirrhosis and 18 with hepatocellular carcinoma), and 21 age-matched controls (11 men and 10 women). Serum soluble **ICAM**-1 was measured using an enzyme immunoassay. Skin tests for seven different antigens (tetanus, diphtheria, streptococcus group C, tuberculin, **Candida**, tricophyton, and proteus) were considered positive when diameters gtoreq 2 mm were recorded; the diameters of positive tests were added to calculate a cumulative score. Results-Patients with chronic liver disease had fewer positive skin tests (median 2) and a lower cumulative score (median 7) than controls (median 3 and 12, respectively). Multivariate analysis suggested the existence of an independent association between alkaline phosphatase and anergy to skin tests and between soluble **ICAM**-1 concentrations and the cumulative score. Conclusions-The strong association observed between increased soluble **ICAM**-1 concentrations and impairment of delayed-type hypersensitivity skin tests suggests that soluble **ICAM**-1 may be implicated in the immune depression seen in patients with chronic liver disease.



12126067 BIOSIS NO.: 199900420916
Assessment of certain neutrophil receptors, opsonophagocytosis and soluble intercellular adhesion molecule-1 (**ICAM**-1) following thermal injury.
AUTHOR: Ahmed Shehab El-Din Samy(a); El-Shahat Aref Salah; Saad Salama Osama
AUTHOR ADDRESS: (a)Plastic, Reconstructive and Burn Unit, Faculty of Medicine, Mansoura University, Mansoura**Egypt
JOURNAL: Burns 25 (5):p395-401 Aug., 1999
ISSN: 0305-4179
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Polymorphonuclear leukocytes (PMLs) play a key role in host defense, and phagocyte dysfunction has been associated with increased susceptibility to infections in patients with thermal injury. Intercellular adhesion molecule-1 (**ICAM**-1) plays a role in leukocyte accumulation and extravasation. Therefore, the aim of the present study was to assess the PMLs expression of opsonin receptors: Fcgamma RIII, CR1 and CR3; opsonophagocytosis of PMLs and plasma soluble **ICAM**-1. Flow cytometric analysis (FCM) was used to study PMLs expression of IgG Fc-receptor III (Fcgamma RIII) as well as the complement receptors CR1 (receptor for C3b) and CR3 (receptor for C3bi) in 23 patients with large burns. Analysis of PML complement- and immunoglobulin-mediated phagocytosis of **Candida** albicans were performed in parallel using the phagocytic index. Plasma sICAM-1 was determined using ELISA. This study revealed a significant increase, with variable degrees, in CR1 and CR3-dependent fluorescence, complement-mediated phagocytosis of C. albicans and plasma sIGAM-1 that started at day 2 and remained for about 20 days before normalization. In contrast, Fcgamma RIII-dependent fluorescence and Ig-mediated phagocytosis were significantly decreased versus the control values. These results demonstrate significant changes of PMLs opsonin receptors expression and opsonophagocytosis documenting systemic activator of PMLs after large burns. In addition, elevation of plasma sICAM-1 may enhance the harmful effect of neutrophil activation through leukocyte accumulation and extravasation through endothelial damage in skin and in lung.

12215770 BIOSIS NO.: 199900510619
Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization.
AUTHOR: Mulero-Marchese Rocio D; Blank Kenneth J; Sieck Thomas G(a)
AUTHOR ADDRESS: (a)Dept. of Pathology MS 435, MCP Hahnemann University, Broad and Vine Sts, Philadelphia, PA, 19102**USA
JOURNAL: Immunogenetics 49 (11-12):p973-980 Oct., 1999
ISSN: 0093-7711
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: We have previously demonstrated a genetic predisposition among mice regarding their ability to be protected against vaginal candidiasis after peripheral immunization. Both BALB/c and (BALB/c X C57BL/6) F1 mice are protected against vaginal candidiasis after subcutaneous immunization with **Candida** albicans extract and C57BL/6 mice are not protected by this immunization. In the present study, the ability of F1-derived immune cells to transfer protection to naive parental strains was observed in BALB/c recipient mice, but not apparent in B6 recipient mice. This result is highly suggestive that the microenvironment of the B6 mouse is responsible for the susceptible phenotype. Genetic studies using (BALB/c X C57BL/6)F1 X C57BL/6 backcross mice demonstrated that two genes appeared to regulate the protective effect of peripheral immunization to vaginal challenge. Microsatellite mapping indicated that candidate loci involved in controlling the immune response to vaginal candidiasis after peripheral immunization included the intercellular adhesion molecule-1 (**ICAM**-1), the **Icam**-1 related sequence 1, and the Fc epsilon RII ($P < 0.01$). Thus, the ability of cells to bind to vaginal endothelial cells may play an important role in protection against vaginal

12415609 BIOSIS NO.: 200000169111
Mechanisms of the proinflammatory response of endothelial cells to **Candida** albicans infection.
AUTHOR: Orozco Alison S; Zhou Xiang; Filler Scott G(a)
AUTHOR ADDRESS: (a)Division of Infectious Diseases, Harbor-UCLA Medical Center, 1000 West Carson St., RB-2, Torrance, CA, 90509**USA
JOURNAL: Infection and Immunity. 68 (3):p1134-1141 March, 2000
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Endothelial cells can influence significantly the host inflammatory response against blood-borne microbial pathogens. Previously, we found that endothelial cells respond to in vitro infection with **Candida** albicans by secreting interleukin 8 (IL-8) and expressing E-selectin, intercellular adhesion molecule 1 (**ICAM**-1), and vascular cell adhesion molecule 1 (VCAM-1). We have now examined the mechanisms mediating this endothelial cell response. We determined that C. albicans stimulated endothelial cells to synthesize tumor necrosis factor alpha (TNF-alpha), which in turn induced these infected cells to secrete IL-8 and express E-selectin by an autocrine mechanism. Expression of VCAM-1 was mediated not only by TNF-alpha but also by IL-1alpha and IL-1beta, all of which were synthesized by endothelial cells in response to C. albicans. These three cytokines remained primarily cell associated rather than being secreted. Candidal induction of **ICAM**-1 expression was independent of TNF-alpha, IL-1alpha, and IL-1beta. These observations demonstrate that different proinflammatory endothelial cell responses to C. albicans are induced by distinct mechanisms. A clear understanding of these mechanisms is important for therapeutically modulating the endothelial cell response to C. albicans and perhaps other opportunistic pathogens that disseminate hematogenously.

13015069 BIOSIS NO.: 200100222218
Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: Characterization of inflammatory cells and mediators in the skin by immunohistochemistry.
AUTHOR: Faergemann J(a); Bergbrant I-M; Dohse M; Scott A; Westgate G
AUTHOR ADDRESS: (a)Department of Dermatology, Sahlgrenska University Hospital, S-413 45, Gothenburg: jan.faergemann@derm.gu.se**Sweden
JOURNAL: British Journal of Dermatology 144 (3):p549-556 March, 2001
MEDIUM: print
ISSN: 0007-0963
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Background The fact that Pityrosporum ovale plays a part in seborrhoeic dermatitis is well established but the mechanism of this relationship has not been established. Objectives To compare the number and type of inflammatory cells and mediators in skin biopsies from normal and lesional skin from the trunk and scalp in patients with seborrhoeic dermatitis, Pityrosporum (Malassezia) folliculitis and in normal skin from healthy controls. Methods The skin biopsies were stained using the labelled Streptavidin-biotin method. The following markers were studied: CD4, CD8, CD68, HLA-DR, NK1, CD16, C1q, C3c, IgG, CD54 (**ICAM**-1), interleukin (IL) -1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-10, IL-12, tumour necrosis factor-alpha and interferon-gamma. Results HLA-DR + cells were seen in the highest number, and were higher in lesional skin compared with normal skin from both patients and healthy volunteers. **ICAM**-1 expression was also increased in lesional skin. C1q and the interleukins showed an increased cellular and intercellular staining in patients compared with healthy controls and the intercellular staining was often more intense in lesions compared with non-lesional skin. Staining was often more intense when Malassezia (Pityrosporum ovale) yeast cells were present. Conclusions An increase in NK1 + and CD16+ cells in combination with complement activation indicates that an irritant non-immunogenic stimulation of the immune system is important. The result with the interleukins showed both an increase in the production of inflammatory interleukins as well as in the regulatory interleukins for both TH1 and TH2 cells. Similarities to the immune response described for **Candida** albicans infections indicate the role of Malassezia in the skin response in seborrhoeic dermatitis and Pityrosporum folliculitis.

Set	Items	Description
S1	21	E1-E4
S2	21	RD S1 (unique items)
S3	49	ICAM? AND CANDIDA
S4	25	RD S3 (unique items)
S5	6	ICAM? (20N) (VACCIN? OR ADJUVANT? OR IMMUNO?) AND CANDIDA
S6	0	RD S5
S7	4	RD S5 (unique items)
S8	1	ICAM? (20N) (VACCIN? OR ADJUVANT?) AND CANDIDA
S9	111	ICAM?(20N)(ADJUVANT? OR VACCIN?)
S10	60	RD S9 (unique items)
S11	1	S10 AND CANDIDA
S12	1	S11 AND (PATHOGEN? OR FUNGAL OR FUNGUS)
S13	22	S9 AND (PATHOGEN? OR FUNGAL OR FUNGUS)
S14	16	RD S13 (unique items)

14/7/11 . (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130120467 CA: 130(10)120467g PATENT
Cell line for propagating receptor binding site-deleted FMDV
INVENTOR(AUTHOR): Mason, Peter W.; Baxt, Barry; Reider, Elizabeth; Berinstein, Analia; Kang, Angray S.
LOCATION: USA
ASSIGNEE: United States Dept. of Agriculture
PATENT: United States ; US 5866416 A DATE: 19990202
APPLICATION: US 593999 (19960624) *US 418716 (19950407)
PAGES: 14 pp., Cont.-in-part of U.S. 5,612,040. CODEN: USXXAM
LANGUAGE: English CLASS: 435328000; A61K-039/135A; C07H-021/04B; C07K-014/705B; C12N-005/10B

12645982 BIOSIS NO.: 200000399484
LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: Involvement of CD4+ T cells in protection.
AUTHOR: Sin Jeong-Im; Kim Jong; Dang Kesen; Lee Dan; Patchuk Catherine; Satishchandran C; Weiner David B(a)
AUTHOR ADDRESS: (a)Department of Pathology and Laboratory Medicine, University of Pennsylvania, 422 Curie Drive, 505 Stellar-Chance Lab, Philadelphia, PA, 19104**USA
JOURNAL: Cellular Immunology 203 (1):p19-28 July 10, 2000
MEDIUM: print
ISSN: 0008-8749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Adhesion molecules are important for cell trafficking and delivery of secondary signals for stimulation of T cells and antigen-presenting cells (APCs) in a variety of immune and inflammatory responses. Adhesion molecules lymphocyte function-associated antigen (LFA)-1 and CD2 on T cells recognize intercellular adhesion molecule (ICAM)-1 and LFA-3 on APCs, respectively. Recent studies have suggested that these molecules might play a regulatory role in antigen-specific immune responses. To investigate specific roles of adhesion molecules in immune induction we coimmunized LFA-3 and **ICAM**-1 cDNAs with a gD plasmid **vaccine** and then analyzed immune modulatory effects and protection against lethal herpes simplex virus (HSV)-2 challenge. We observed that gD-specific IgG production was enhanced by LFA-3 coinjection. However, little change in IgG production was observed by ICAM-1 coinjection. Furthermore, both Th1 and Th2 IgG isotype production was driven by LFA-3. LFA-3 also enhanced Th cell proliferative responses and production of interleukin (IL)-2, interferon-gamma, IL-4, and IL-10 from splenocytes. In contrast, ICAM-1 showed slightly increasing effects on T-cell proliferation responses and cytokine production. beta-Chemokine production (RANTES, MIP-1alpha, and MCP-1) was also influenced by LFA-3 or ICAM-1. When animals were challenged with a lethal dose of HSV-2, LFA-3-coimmunized animals exhibited an enhanced survival rate, as compared to animals given **ICAM**-1 or gD DNA **vaccine** alone. This enhanced protection appears to be mediated by CD4+ T cells, as determined by in vitro and in vivo T-cell subset deletion. These studies demonstrate that adhesion molecule LFA-3 can play an important role in generating protective antigen-specific immunity in the HSV model system through increased induction of CD4+ Th1 T-cell subset.

14/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

4.

```
                                    bbb                lll
                                     bb                 ll
pp ppp    ggg gg  aaaa    mm  mm    bb       eeee      ll
 pp  pp gg  gg       aa  mmmmmmmm  bbbbb  ee  ee     ll
 pp  pp gg  gg    aaaaa  mmmmmmmm  bb  bb eeeeee     ll
 ppppp   ggggg  aa  aa   mm m mm  bb  bb ee         ll
 pp         gg   aaa aa mm    mm bb bbb   eeee     llll
pppp    ggggg
```

```
  11      8888   777777
 111     88  88  77  77
  11     88  88      77
  11      8888      77
  11     88  88    77
  11     88  88    77
111111    8888     77
```

7/18/01

t s16/kwic/all

>>>KWIC option is not available in file(s): 399

16/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: administration of recombinant fowlpox vector expressing CEA and three different costimulatory molecule transgenes (B7-1, **ICAM** -1, LFA-3, designated rF-CEA/TRICOM) was more potent in inducing CEA-specific T-cell responses than four **vaccinations** with rF-CEA or two vaccinations with rF-CEA/B7-1. Moreover, up to four...

16/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

ABSTRACT: This work studied the approach of **vaccination** by utilizing ultraviolet attenuated S. mansoni cercariae on two surface adhesion molecules expression, intercellular adhesion molecules 1 (**ICAM**-1) and vascular cell adhesion molecules 1 (VCAM-1). ICAM-1 and VCAM-1 expression...

...1 expression was mainly localized on granuloma cells. (2) The video count areas that expressed **ICAM**-1 and VCAM-1 were markedly increased in **vaccinated** than naive animals. The **ICAM**-1 intensity was (58.7%) in VC while (31.1%) in NC mice group. (3...

16/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: cells had higher levels of major histocompatibility complex (MHC) class I and intercellular adhesion molecule (**ICAM**-1) expression than the MAT-LyLu cells. However, both tumour cell lines were rejected in their allogeneic hosts. Prophylactic **vaccination** with allogeneic MAT-LyLu cells protected against PAIII tumour challenge in Lobund-Wistar rats, with...

16/KWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: To investigate specific roles of adhesion molecules in immune induction we coimmunized LFA-3 and **ICAM**-1 cDNAs with a gD plasmid **vaccine** and then analyzed immune modulatory effects and protection against lethal herpes simplex virus (HSV)-2...

...2, LFA-3-coimmunized animals exhibited an enhanced survival rate, as compared to animals given **ICAM**-1 or gD DNA **vaccine** alone. This enhanced protection appears to be mediated by CD4+ T cells, as determined by...

16/KWIC/5 (Item 5 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: DBLbeta domain from A4var PfEMP1 in ICAM-1 adhesion. The identification of a P. falciparum **ICAM**-1 binding domain may clarify

mechanisms responsible for the pathogenesis of cerebral malaria and lead to interventions or **vaccines** that reduce malarial disease.

16/KWIC/6 (Item 6 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: efficiently express multiple genes. Murine cells provided with signal 1 and infected with either recombinant **vaccinia** or avipox vectors containing a TRIad of COstimulatory Molecules (B7-1/**ICAM** -1/LFA-3, designated TRICOM) induced the activation of T cells to a far greater...

16/KWIC/7 (Item 7 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: in tumorigenicity of gliomas and the antitumor effects of glioma cells genetically engineered to express **ICAM**-1. Mouse glioma cells transfected with **ICAM**-1 grew in T-cell deficient mice but not in syngeneic mice. **Vaccination** with **ICAM**-1-transfected tumor cells markedly inhibited the growth of subcutaneously inoculated gliomas but not gliomas...

...CD8+ T and NK cells were all required to produce the antitumor effect of SR/**ICAM**-1. In this study, we demonstrated the therapeutic potential of **vaccination** with **ICAM**-1-overexpressing tumor cells for the control of the tumor growth.

16/KWIC/8 (Item 8 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: IL-12) and genetically engineered glioma cells expressing B7-1 or both B7-1 and **ICAM**-1. **Vaccination** of mice with B7-1-expressing tumor cells substantially inhibited the growth of subcutaneously inoculated...

...expressing tumor cells or rIL-12 alone. Our murine brain tumor model also showed that **vaccination** with tumor cells expressing both B7-1 and **ICAM**-1 combined with rIL-12 prolonged survival. We have demonstrated the therapeutic potential of **vaccination** with rIL-12 and tumor cells expressing both B7-1 and **ICAM**-1 in the control of glioma growth.

16/KWIC/9 (Item 9 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

Admixture of recombinant **vaccinia** viruses expressing CEA and T-cell costimulatory molecules B7-1, B7-2, **ICAM**-1, murine LFA-3 analogue or CD70 induces anti-tumor immunity.

16/KWIC/10 (Item 10 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: Here, we demonstrate strain-specific differences in the ability of measles virus (MV) to induce **ICAM**-1 expression. The **vaccine** strain Moraten (Mor) rapidly induced high levels of **ICAM**-1 mRNA and protein expression, whereas the **vaccine** strain CAM-70 and the Edmonston wild type (Edwt) strain were far less effective, even...

16/KWIC/11 (Item 11 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: disrupted IFNgamma receptor gene have been used to dissect the role of the cytokine. After **vaccination** and challenge, CD4+ T cells from the pulmonary interstitium have reduced levels of **ICAM**-1 and LFA-1 expression, compared to wild-type animals, which coincides with a reduced...

16/KWIC/12 (Item 12 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: repeatedly BCG-treated mice at age 120 days as compared with controls and single BCG-**vaccination** groups, we could not detect significant differences in the Intracellular adhesion molecule-1 (**ICAM**-1) expression between the various groups. There were no differences in weight gain and blood...

16/KWIC/13 (Item 13 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

ICAM-1 and iNOS expression increased in the skin of mice after **vaccination** with gamma-irradiated cercariae of Schistosoma mansoni.

...ABSTRACT: in the skin at 24 hr (in multiply infected animals) and at 48 hr (in **vaccinated** animals) after a challenge infection. Along with the massive cellular infiltration there was an increased tissue expression of **ICAM**-1 and mRNA for iNOS in the skin of sensitized animals. Further analysis showed that...

...important for the initial cutaneous inflammatory/immune responses to migrating schistosomula of S. mansoni in **vaccinated** animals. On the contrary, in naive animals a potential parasite-induced suppression of **ICAM**-1 may play an important role in reducing cellular reaction in the skin and consequently...

16/KWIC/14 (Item 14 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: interferon-gamma (IFN-gamma) was also found to be induced in those patients receiving the **vaccine**. In vitro studies indicated that the expression of MHC I, MHC II, and **ICAM** I in ovarian tumor cells were upregulated in response to IFN-gamma. Such tumor cells...

16/KWIC/15 (Item 15 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: unmodified tumor cells. Most importantly, administration of tumor cells genetically modified with genes encoding xenogeneic **ICAM**-1 can facilitate an immunological response to genetically unaltered preexisting tumors. Transferring splenocytes from animals ' **vaccinated**' with the xenogeneic **ICAM**-1 gene altered tumor cells was able to transfer the antitumor response into recipient animals ...

16/KWIC/16 (Item 16 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: and in their ability to bind different ligands, including fibronectin and the intercellular adhesion molecule **ICAM**-1.

Vaccinia-virus-infected CD43-knockout mice mounted an augmented anti-**vaccinia** cytotoxic T-cell response compared with their wild-type littermates, yet developed an increased virus...

16/KWIC/17 (Item 17 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: and 2 IFN is not cell-cycle dependent. Other viruses, including double-stranded DNA viruses, **vaccinia**, and adenovirus 2 and 5 and the single, positive-stranded RNA alphavirus, Semiliki Forest virus, did not induce **ICAM**-1 expression on fibroblasts after 24 hr. Another alphavirus, Ross river, was able to induce...

16/KWIC/18 (Item 18 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

Defective antigen presentation by monocytes in ESRD patients not responding to hepatitis B **vaccination**: Impaired HBsAg internalization and expression of **ICAM**-1 and HLA-DR/Ia molecules.

16/KWIC/19 (Item 19 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: data indicate that clinical inflammation and regression of metastatic melanoma induced by autologous melanoma-cell **vaccine** involves activated T cells with cytotoxic-suppressor phenotype and dendritic cells putatively capable of local antigen presentation. **ICAM**-1 upregulation on melanoma cells is a likely mediator of ligand interaction between infiltrating T...

16/KWIC/20 (Item 20 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

HLA-DR and **ICAM**-1 expression on **vaccine** tumor cells predict clinical response to a human colon carcinoma **vaccine**.

16/KWIC/21 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2001 Elsevier Science B.V. All rts. reserv.

...this was accomplished by their infection with recombinant poxviruses (either the replication-defective avipox or **vaccinia**), which contain transgenes for a triad of costimulatory molecules (B7-1, **ICAM**-1 and LFA-3, designated TRICOM). APCs infected with TRICOM vectors are shown to significantly...

16/KWIC/22 (Item 2 from file: 73)
DIALOG(R)File 73:(c) 2001 Elsevier Science B.V. All rts. reserv.

...the B7-1 co-stimulatory molecule is expressed in a tumor-cell vaccine via a **vaccinia** vs a retroviral vector; 4) the use of recombinant poxviruses containing the genes for the co-stimulatory molecules **ICAM** -1 or LFA-3 to induce antitumor immunity; and 5) the use of poxvirus vectors...

16/KWIC/23 (Item 3 from file: 73)
DIALOG(R)File 73:(c) 2001 Elsevier Science B.V. All rts. reserv.

...responses. In this study, we report the construction,

characterization, and immunological consequences of a recombinant **vaccinia** virus expressing murine **ICAM**-1. **Vaccinia** virus represents an attractive vector for the delivery of molecules such as **ICAM**-1 due to its wide host range, rapid infection, and functional expression of inserted gene...

...evidence for recall response and immunological memory. These studies demonstrated the utility of a recombinant **vaccinia** virus to deliver and efficiently express **ICAM**-1 molecules on tumor cells for potential gene therapy and recombinant approaches to cancer immunotherapy.

16/KWIC/24 (Item 4 from file: 73)

...interferon-gamma, (IFN-gamma) was also found to be induced in those patients receiving the **vaccine**. In vitro studies indicated that the expression of MHC I, MHC II, and **ICAM** I in ovarian tumor cells were upregulated in response to IFN-gamma. Such tumor cells...

16/KWIC/25 (Item 5 from file: 73)

...of the six cases which were examined, the expression of HLA class I and/or **ICAM1** was increased. These four cases were of the six previously mentioned. These results suggest that tumor **vaccination** therapy with TNF gene transduction may be useful in some gastrointestinal tract cancer patients, inducing...

16/KWIC/26 (Item 6 from file: 73)

HLA-DR and **ICAM**-1 expression on human colon carcinoma **vaccines** predicts clinical response to active specific immunotherapy

...that they had a 4.67-fold greater chance of remaining disease free if their **vaccines** had >25% of cells expressing HLA-DR or **ICAM**-1. This observation suggests that the tumor cell itself acts as the primary antigen presenting...

...T cells. Dissociated colon tumor metastases had higher percentages of cells expressing HLA-DR and **ICAM**-1 than those prepared from Dukes' stage D primary tumors, suggesting that **vaccines** prepared from dissociated metastatic tumors may be more immunogenic than colon primary tumors in patients with advanced disease. **Vaccines** from melanoma patients had low frequencies of HLA-DR-positive cells but high frequencies of **ICAM**-1 -positive cells, with 74% of individuals having >25% HLA-DR or **ICAM**-1 expressing cells in their **vaccines**. Ninety-five percent of all renal cell carcinoma **vaccine** preparations had >25% positive HLA-DR and **ICAM**-1 expressing cells. However, 34% of the time, dissociated renal cell carcinomas contained <25% tumor...

16/KWIC/27 (Item 1 from file: 155)

This work studied the approach of **vaccination** by utilizing ultraviolet attenuated S. mansoni cercariae on two surface adhesion molecules expression, intercellular adhesion molecules 1 (**ICAM**-1) and vascular cell adhesion molecules 1(VCAM-1). ICAM-1 and VCAM-1 expression...

... 1 expression was mainly localized on granuloma cells. (2) The video count areas that expressed **ICAM**-1 and VCAM-1 were markedly increased

in **vaccinated** than naive animals. The **ICAM**-1 intensity was (58.7%) in VC while (31.1%) in NC mice group. (3...

16/KWIC/28 (Item 2 from file: 155)
DIALOG(R)File 155:(c) format only 2001 Dialog Corporation. All rts. reserv.

... interferon-gamma (IFN-gamma) was also found to be induced in those patients receiving the **vaccine**. In vitro studies indicated that the expression of MHC I, MHC II, and **ICAM** I in ovarian tumor cells were upregulated in response to IFN-gamma. Such tumor cells...

16/KWIC/29 (Item 3 from file: 155)
DIALOG(R)File 155:(c) format only 2001 Dialog Corporation. All rts. reserv.

... fragments of diphtheria toxin, topical tumour necrosis factor inhibitors, topical retinoids, T cell receptor peptide **vaccines** and intercellular adhesion molecule 1 (**ICAM** -1) antisense oligonucleotides.
? t s16/3/all

16/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

13115762 BIOSIS NO.: 200100322911
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
AUTHOR: Grosenbach Douglas W; Barrientos Jacqueline C; Schlom Jeffrey(a); Hodge James W
AUTHOR ADDRESS: (a)Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, 10 Center Drive, Room 8B09, Bethesda, MD, 20892: js141c@nih.gov**USA
JOURNAL: Cancer Research 61 (11):p4497-4505 June 1, 2001
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12817459 BIOSIS NO.: 200100024608
Effect of vaccination on expression of intracellular adhesion molecules 1 and vascular cell adhesion molecules 1 in murine schistosomiasis.
AUTHOR: Sayed El Ahl Saedia A(a); Hussein Rafiaa R(a); Ahmed Doaa A(a); El Shiekh Nabila A(a)
AUTHOR ADDRESS: (a)Department of Parasitology and Microbiology, Faculty of Medicine For Girls, AL Azhar University, Cairo, Nasr City**Egypt
JOURNAL: Journal of the Egyptian Society of Parasitology 30 (3):p829-838 December, 2000
MEDIUM: print
ISSN: 1110-0583
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12758331 BIOSIS NO.: 200000511954
Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer.
AUTHOR: Hrouda D; Todryk S M; Perry M J A; Souberbielle B E; Kayaga J; Kirby R S; Dalgleish A G(a)
AUTHOR ADDRESS: (a)Division of Oncology, St. George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE**UK
JOURNAL: BJU International 86 (6):p742-748 October, 2000
MEDIUM: print
ISSN: 1464-4096
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12645982 BIOSIS NO.: 200000399484
LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: Involvement of CD4+ T cells in protection.
AUTHOR: Sin Jeong-Im; Kim Jong; Dang Kesen; Lee Dan; Patchuk Catherine; Satishchandran C; Weiner David B(a)
AUTHOR ADDRESS: (a)Department of Pathology and Laboratory Medicine, University of Pennsylvania, 422 Curie Drive, 505 Stellar-Chance Lab, Philadelphia, PA, 19104**USA
JOURNAL: Cellular Immunology 203 (1):p19-28 July 10, 2000
MEDIUM: print
ISSN: 0008-8749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12403258 BIOSIS NO.: 200000156760
Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: A parasite adhesion trait implicated in cerebral malaria.
AUTHOR: Smith Joseph D; Craig Alister G; Kriek Neline; Hudson-Taylor Diana; Kyes Sue; Fagen Toby; Pinches Robert; Baruch Dror I; Newbold Chris I(a); Miller Louis H
AUTHOR ADDRESS: (a)Molecular Parasitology Group, Institute of Molecular Medicine, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 9DU**UK
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America. 97 (4):p1766-1771 Feb. 15, 2000
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

12305185 BIOSIS NO.: 200000063052
A triad of costimulatory molecules synergize to amplify T-cell activation.
AUTHOR: Hodge James W; Sabzevari Helen; Yafal Alicia Gomez; Gritz Linda; Lorenz Matthias G O; Schlom Jeffrey(a)
AUTHOR ADDRESS: (a)Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, 10 Center Drive, Room 8B07, Bethesda, MD**USA
JOURNAL: Cancer Research 59 (22):p5800-5807 Nov. 15, 1999
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12133767 BIOSIS NO.: 199900428616
Induction of antitumor immunity using Intercellular adhesion molecule 1 (ICAM-1) transfection in mouse glioma cells.
AUTHOR: Kikuchi Tetsuro(a); Joki Tatsuhiro; Akasaki Yasuharu; Abe Toshiaki; Ohno Tsuneya
AUTHOR ADDRESS: (a)Division of Oncology, Institute of DNA Medicine, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105**Japan
JOURNAL: Cancer Letters 142 (2):p201-206 Aug. 3, 1999
ISSN: 0304-3835
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12099733 BIOSIS NO.: 199900394582
Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12.
AUTHOR: Joki Tatsuhiro; Kikuchi Tetsuro(a); Akasaki Yasuharu; Saitoh Saburo ; Abe Toshiaki; Ohno Tsuneya
AUTHOR ADDRESS: (a)Department of Oncology, Institute of DNA Medicine, Jikei University School of Medicine, 3-25-8 N**Japan
JOURNAL: International Journal of Cancer 82 (5):p714-720 Aug. 27, 1999
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

16/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11929096 BIOSIS NO.: 199900175205
Admixture of recombinant **vaccinia** viruses expressing CEA and T-cell costimulatory molecules B7-1, B7-2, **ICAM**-1, murine LFA-3 analogue or CD70 induces anti-tumor immunity.

AUTHOR: Lorenz Matthias G O; Schlom Jeffrey; Hodge James W
AUTHOR ADDRESS: Lab. Tumor Immunology Biol., National Cancer Inst., NIH, Bethesda, MD 20982**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 40p423 March, 1999
CONFERENCE/MEETING: 90th Annual Meeting of the American Association for Cancer Research Philadelphia, Pennsylvania, USA April 10-14, 1999
SPONSOR: American Association for Cancer Research
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English

16/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11798096 BIOSIS NO.: 199900044205
Induction of intercellular adhesion molecule 1 gene expression by measles virus in human umbilical vein endothelial cells.
AUTHOR: Harcourt Brian H; Rota Paul A; Hummel Kimberly B; Bellini William J ; Offermann Margaret K(a)
AUTHOR ADDRESS: (a)Winship Cancer Cent., 1365 B Clifton Road, Atlanta, GA 30322**USA
JOURNAL: Journal of Medical Virology 57 (1):p9-16 Jan., 1999
ISSN: 0146-6615
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11431349 BIOSIS NO.: 199800212681
Interferon gamma is a key cytokine in lung phase immunity to schistosomes but what is its precise role?
AUTHOR: Wilson R A(a)
AUTHOR ADDRESS: (a)Dep. Biol., Univ. York, P.O. Box 373, York YO1 5YW**UK
JOURNAL: Brazilian Journal of Medical and Biological Research 31 (1):p157-161 Jan., 1998
ISSN: 0100-879X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11296785 BIOSIS NO.: 199800078117
Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice.
AUTHOR: Shehadeh Naim(a); Etzioni Amos; Cahana Alfred; Teninboum Galilah; Gorodetsky Boris; Barzilai David; Karnieli Edi
AUTHOR ADDRESS: (a)Pediataics A, Rambam Med. Cent., 31096 Haifa**Israel
JOURNAL: Israel Journal of Medical Sciences 33 (11):p711-715 Nov., 1997
ISSN: 0021-2180
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11041409 BIOSIS NO.: 199799662554
ICAM-1 and iNOS expression increased in the skin of mice after **vaccination** with gamma-irradiated cercariae of Schistosoma mansoni.
AUTHOR: Ramaswamy K; He Yi-Xun; Salafsky B
AUTHOR ADDRESS: Dep. Biomed. Sciences, Coll. Med., Univ. Illinois, Rockford, IL 61107**USA
JOURNAL: Experimental Parasitology 86 (2):p118-132 1997
ISSN: 0014-4894
RECORD TYPE: Abstract
LANGUAGE: English

16/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10886858 BIOSIS NO.: 199799508003
OVAREX Mab-B43.13:IFN-y could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells.
AUTHOR: Madiyalakan R(a); Yang R; Schultes B C; Baum R P; Noujam A A
AUTHOR ADDRESS: (a)AltaRex Inc., 300 Campus Tower, 8625 112 St., Edmonton, AB**Canada
JOURNAL: Hybridoma 16 (1):p41-45 1997
ISSN: 0272-457X
RECORD TYPE: Abstract
LANGUAGE: English

16/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10469456 BIOSIS NO.: 199699090601
Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity.
AUTHOR: Wei K; Wilson J G; Jurgensen C H; Iannone M A; Wolberg G; Huber B E(a)
AUTHOR ADDRESS: (a)Dep. Cell Biol., Wellcome Res. Lab., 3030 Cornwallis Road, Research Triangle Park, NC 27709**USA
JOURNAL: Gene Therapy 3 (6):p531-541 1996
ISSN: 0969-7128
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10087890 BIOSIS NO.: 199598542808
Negative regulation of T-cell adhesion and activation by CD43.
AUTHOR: Manjunath N; Correa Mariangela; Ardman Margarett; Ardman Blair
AUTHOR ADDRESS: Dep. Med., Div. Hematol.-Oncol., New England Med. Cent. Hospitals, 750 Washington St., Boston, MA 02**USA
JOURNAL: Nature (London) 377 (6549):p535-538 1995
ISSN: 0028-0836
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09875334 BIOSIS NO.: 199598330252
Early induction of interferon-independent virus-specific ICAM-1 (CD54) expression by flavivirus in quiescent but not proliferating fibroblasts: Implications for virus-host interactions.
AUTHOR: Shen Jie; Devery Jannine M; King Nicholas J C(a)
AUTHOR ADDRESS: (a)Dep. Pathol., Univ. Sydney, Sydney, NSW 2006**Australia
JOURNAL: Virology 208 (2):p437-449 1995
ISSN: 0042-6822
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09780680 BIOSIS NO.: 199598235598
Defective antigen presentation by monocytes in ESRD patients not responding to hepatitis B **vaccination**: Impaired HBsAg internalization and expression of **ICAM**-1 and HLA-DR/Ia molecules.
AUTHOR: Stachowski J(a); Barth C; Pollok M; Michalkiewicz J; Madalinski K; Maciejewski J; Baldamis C A
AUTHOR ADDRESS: (a)Dep. Nephrol., 2nd Clin. Child. Dis., Univ. Sch. Med. Sci., ul. Szpitalna 27/33, 61-572 Poznan**Poland
JOURNAL: Mediators of Inflammation 4 (1):p49-54 1995
ISSN: 0962-9351
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08844237 BIOSIS NO.: 199395133588
Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: Relevance to immunologic regression and immunotherapy.
AUTHOR: Murphy George F(a); Radu Antoaneta; Kaminer Michael; Berd David
AUTHOR ADDRESS: (a)235B Clinical Res. Build., 422 Curie Boulevard, Philadelphia, PA 19104
JOURNAL: Journal of Investigative Dermatology 100 (3 SUPPL.):p335S-341S 1993
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08641545 BIOSIS NO.: 199345059620
HLA-DR and **ICAM**-1 expression on **vaccine** tumor cells predict clinical response to a human colon carcinoma **vaccine**.
AUTHOR: Ransom J H; Pelle B A; Brandhorst J; Hanna M G Jr
AUTHOR ADDRESS: Organon Teknika/Biotechnol. Res. Inst., Rockville, MD 20850**USA

JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 34 (0):p489 1993
CONFERENCE/MEETING: 84th Annual Meeting of the American Association for Cancer Research Orlando, Florida, USA May 19-22, 1993
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English

16/3/21 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11202587 EMBASE No: 2001217253
Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors
Rad A.N.; Schlom J.; Hodge J.W.
J. Schlom, Lab. Tumor Immunology/Biology, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1750 United States
AUTHOR EMAIL: js141c@nih.gov
Critical Reviews in Oncology/Hematology (CRIT. REV. ONCOL. HEMATOL.) (Ireland) 2001, 39/1-2 (43-57)
CODEN: CCRHE ISSN: 1040-8428
PUBLISHER ITEM IDENTIFIER: S1040842801001238
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 29

16/3/22 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

07891359 EMBASE No: 1999364871
The diversity of T-cell co-stimulation in the induction of antitumor immunity
Schlom J.; Hodge J.W.
J. Schlom, Laboratory Tumor Immunology Biology, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892-1750 United States
AUTHOR EMAIL: js141c@nih.gov
Immunological Reviews (IMMUNOL. REV.) (Denmark) 1999, 170/- (73-84)
CODEN: IMRED ISSN: 0105-2896
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 64

16/3/23 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

06880861 EMBASE No: 1997165194
Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses
Uzendoski K.; Kantor J.A.; Abrams S.I.; Schlom J.; Hodge J.W.
Dr. J. Schlom, Laboratory Tumor Immunology Biology, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1750 United States
Human Gene Therapy (HUM. GENE THER.) (United States) 1997, 8/7 (851-860)
CODEN: HGTHE ISSN: 1043-0342
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 23

16/3/24 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

06821673 EMBASE No: 1997104167
OVAREX(RM) MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells
Madiyalakan R.; Yang R.; Schultes B.C.; Baum R.P.; Noujaim A.A.
Dr. R. Madiyalakan, AltaRex Inc., 300 Campus Tower, 8625 112 Street, Edmonton, Alta. Canada
Hybridoma (HYBRIDOMA) (United States) 1997, 16/1 (41-45)
CODEN: HYBRD ISSN: 0272-457X
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 21

16/3/25 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

06080272 EMBASE No: 1995110759
Augmented anti-tumor effects of cytotoxic T lymphocytes (CTL) induced by TNF-gene transduced autologous human cancer cells
Sato Y.; Hirayama M.; Koshita Y.; Matsuyama T.; Neda H.; Lu Y.; Watanabe N.; Kohgo Y.; Niitsu Y.; Hamada H.; Wakimoto H.
4th Department of Internal Medicine, Sapporo Medical Univ. School of Med., South-1, West-16,Chuo-ku, Sapporo 060 Japan
Biotherapy (BIOTHERAPY) (Japan) 1995, 9/3 (300-301)
CODEN: BITPE ISSN: 0914-2223
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: JAPANESE SUMMARY LANGUAGE: ENGLISH

16/3/26 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

05473850 EMBASE No: 1993241949
HLA-DR and **ICAM**-1 expression on human colon carcinoma **vaccines** predicts clinical response to active specific immunotherapy
Ransom J.H.; Pelle B.A.; Brandhorst J.S.; Hoover Jr. H.C.; Vermorken J.B.; Avis F.P.; Galligioni E.; Fenton R.G.; Hanna Jr. M.G.
Organon Teknika/Biolechnol Rsrch Ins, 1330 Piccard Drive,Rockville, MD 20850 United States
Vaccine Research (VACCINE RES.) (United States) 1993, 2/2 (65-78)
CODEN: VAREE ISSN: 1056-7909
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

16/3/27 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2001 Dialog Corporation. All rts. reserv.

11373881 21069279 PMID: 11198381
Effect of vaccination on expression of intracellular adhesion molecules 1 and vascular cell adhesion molecules 1 in murine schistosomiasis.
el-Ahl SA; Hussein RR; Ahmed DA; el-Shiekh NA
Department of Parasitology and Microbiology, Faculty of Medicine For Girls, Al Azhar University, Cairo, Nasr City, Egypt.
Journal of the Egyptian Society of Parasitology (Egypt) Dec 2000, 30

(3) p829-38, ISSN 0253-5890 Journal Code: IJF
Languages: ENGLISH
Document type: Journal Article
Record type: Completed

16/3/28 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09391431 97239465 PMID: 9085127
OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells.
Madiyalakan R; Yang R; Schultes BC; Baum RP; Noujaim AA
AltaRex Inc., Edmonton, Alberta, Canada.
Hybridoma (UNITED STATES) Feb 1997, 16 (1) p41-5, ISSN 0272-457X Journal Code: GFS
Languages: ENGLISH
Document type: Journal Article
Record type: Completed

16/3/29 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

08952554 96311860 PMID: 8713012
Psoriasis: mechanisms and entry points for possible therapeutic interventions.
Christophers E
Klinik fur Dermatologie, Venereologie und Allergologie, Universitats-Hautlinik, Kiel, Germany.
Australasian journal of dermatology (AUSTRALIA) May 1996, 37 Suppl 1 pS4-6, ISSN 0004-8380 Journal Code: 9IP
Languages: ENGLISH
Document type: Journal Article; Review; Review, Tutorial
Record type: Completed

16/3/30 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

134055239 CA: 134(5)55239a JOURNAL
DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
AUTHOR(S): Rovero, Stefania; Amici, Augusto; Di Carlo, Emma; Bei, Roberto ; Nanni, Patrizia; Quaglino, Elena; Porcedda, Paola; Boggio, Katia; Smorlesi, Arianna; Lollini, Pier-Luigi; Landuzzi, Lorena; Colombo, Mario P. ; Giovarelli, Mirella; Musiani, Piero; Forni, Guido
LOCATION: Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
JOURNAL: J. Immunol. DATE: 2000 VOLUME: 165 NUMBER: 9 PAGES: 5133-5142 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER: American Association of Immunologists

16/3/31 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133361728 CA: 133(26)361728k JOURNAL
Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: Mutated p21 ras oncogene as a model

AUTHOR(S): Kubuschok, Boris; Cochlovius, Christiane; Jung, Wolfram; Schmits, Rudolf; Trumper, Lorenz; Hartmann, Frank; Renner, Christoph; Pfreundschuh, Michael
LOCATION: Department of Internal Medicine I, University of Saarland Medical School, Homburg/Saar, Germany, D-66421
JOURNAL: Cancer Gene Ther. DATE: 2000 VOLUME: 7 NUMBER: 9 PAGES: 1231-1240 CODEN: CGTHEG ISSN: 0929-1903 LANGUAGE: English PUBLISHER: Nature America Inc.

16/3/32 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

132212700 CA: 132(16)212700x PATENT
Low-molecular fragments of hyaluronic acid for the preparation of vaccines
INVENTOR(AUTHOR): Simon, Jan; Martin, Stefan; Termeer, Christian
LOCATION: Germany,
ASSIGNEE: Universitaetsklinikum Freiburg
PATENT: PCT International ; WO 200012122 A2 DATE: 20000309
APPLICATION: WO 99EP6280 (19990826) *DE 19839113 (19980827) *DE 19853066 (19981117)
PAGES: 39 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: A61K-039/00A
DESIGNATED COUNTRIES: AU; CA; JP; US DESIGNATED REGIONAL: AT; BE; CH; CY ; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

16/3/33 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

132121459 CA: 132(10)121459j PATENT
Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method, and pharmaceutical or vaccine applications
INVENTOR(AUTHOR): Zagury, Jean-Francois
LOCATION: Fr.
ASSIGNEE: Vacs International
PATENT: PCT International ; WO 0003732 A1 DATE: 20000127
APPLICATION: WO 99FR1423 (19990615) *FR 989046 (19980715)
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: A61K-039/12A; A61K-039/21B; C07K-016/08B; C07K-016/10B; A61K-039/42B
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

16/3/34 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131198615 CA: 131(15)198615u PATENT
Vaccines, immunotherapeutics and methods for using the same
INVENTOR(AUTHOR): Weiner, David B.; Kim, Jong J.; Sin, Jeong-Im
LOCATION: USA
ASSIGNEE: The Trustees of the University of Pennsylvania
PATENT: PCT International ; WO 9943839 A1 DATE: 19990902
APPLICATION: WO 99US4332 (19990226) *US PV76207 (19980227)
PAGES: 105 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/85A; A61K-048/00B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY;

CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

16/3/35 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131115306 CA: 131(9)115306v PATENT
Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
INVENTOR(AUTHOR): Popescu, Mircea C.; Boni, Lawrence; Robb, Richard J.; Batenjany, Michael M.
LOCATION: USA
ASSIGNEE: Biomira USA Inc.
PATENT: PCT International ; WO 9936085 A1 DATE: 19990722
APPLICATION: WO 99US935 (19990115) *US 71702 (19980116)
PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

16/3/36 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130166883 CA: 130(13)166883t JOURNAL
Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation
AUTHOR(S): Saurwein-Teissl, M.; Zisterer, K.; Schmitt, T. L.; Gluck, R.; Cryz, S.; Grubeck-Loebenstein, B.
LOCATION: Institute for Biomedical Aging Research, Austrian Academy of Sciences, A-6020, Innsbruck, Austria
JOURNAL: Clin. Exp. Immunol. DATE: 1998 VOLUME: 114 NUMBER: 2 PAGES: 271-276 CODEN: CEXIAL ISSN: 0009-9104 LANGUAGE: English PUBLISHER: Blackwell Science Ltd.

16/3/37 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130120467 CA: 130(10)120467g PATENT
Cell line for propagating receptor binding site-deleted FMDV
INVENTOR(AUTHOR): Mason, Peter W.; Baxt, Barry; Reider, Elizabeth; Berinstein, Analia; Kang, Angray S.
LOCATION: USA
ASSIGNEE: United States Dept. of Agriculture
PATENT: United States ; US 5866416 A DATE: 19990202
APPLICATION: US 593999 (19960624) *US 418716 (19950407)
PAGES: 14 pp., Cont.-in-part of U.S. 5,612,040. CODEN: USXXAM
LANGUAGE: English CLASS: 435328000; A61K-039/135A; C07H-021/04B; C07K-014/705B; C12N-005/10B

16/3/38 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129314684 CA: 129(24)314684a JOURNAL
Induction of IL-12 secretion and enhanced surface expression of B7.1/B7.2 and ICAM-1 in human monocytes activated by the vaccine carrier Brucella abortus: correlation with in vivo generation of cellular immune responses
AUTHOR(S): Golding, H.; Zaitseva, M. B.; Lapham, C. K.; Golding, B.
LOCATION: Division of Viral Products, US Food and Drug Administration, Bethesda, MD, 20892, USA
JOURNAL: NATO ASI Ser., Ser. A DATE: 1997 VOLUME: 293 NUMBER: Vaccine Design PAGES: 81-97 CODEN: NALSDJ ISSN: 0258-1213 LANGUAGE: English
PUBLISHER: Plenum Publishing Corp.

16/3/39 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129289179 CA: 129(22)289179e PATENT
Fibrocyte-based cellular therapy formulations
INVENTOR(AUTHOR): Rice, Glenn C.; Bucala, Richard J.
LOCATION: USA
ASSIGNEE: The Picower Institute for Medical Research
PATENT: PCT International ; WO 9843482 A1 DATE: 19981008
APPLICATION: WO 98US6094 (19980327) *US 828415 (19970328)
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A01N-063/00A; A61K-039/00B; A61K-045/05B DESIGNATED COUNTRIES: AU; CA; CN; IL; JP; MX
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

16/3/40 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

129274697 CA: 129(21)274697y PATENT
Rapid production of autologous tumor vaccines by using immunomodulator-encoding herpes simplex virus amplicon vectors
INVENTOR(AUTHOR): Fong, Yuman; Federoff, Howard; Rosenblatt, Joseph D.
LOCATION: USA
ASSIGNEE: Sloan-Kettering Institute for Cancer Research; University of Rochester
PATENT: PCT International ; WO 9842855 A1 DATE: 19981001
APPLICATION: WO 98US5505 (19980320) *US 44005 (19970321)
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/86A; A61K-039/00B; A61K-048/00B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

16/3/41 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

128074292 CA: 128(7)74292e PATENT
Cellular vaccines and immunotherapeutics and methods for their

preparation
INVENTOR(AUTHOR): Guo, Yajun
LOCATION: USA
ASSIGNEE: Guo, Yajun
PATENT: PCT International ; WO 9747271 A2 DATE: 19971218
APPLICATION: WO 97US10238 (19970611) *US 19639 (19960612)
PAGES: 67 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; UZ; VN; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH ; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

16/3/42 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

127032828 CA: 127(3)32828h PATENT
Therapeutic and diagnostic vaccine for the treatment of microbial infections
INVENTOR(AUTHOR): Pascual, David; Bond, Clifford; Burritt, James; Burgess, Don; Glee, Pati; Jutila, John; Jutila, Mark; Bargatze, Robert; Mcfeters, Gordon; Pyle, Barry; Cutler, Jim E.; Han, Yongmoon
LOCATION: USA
ASSIGNEE: Research and Development Institute, Inc.; Pascual, David; Bond, Clifford; Burritt, James; Burgess, Don; Glee, Pati; Jutila, John; Jutila, Mark; Bargatze, Robert; et al.
PATENT: PCT International ; WO 9718790 A2 DATE: 19970529
APPLICATION: WO 96US18796 (19961121) *US 7477 (19951122)
PAGES: 98 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI ; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

16/3/43 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126287718 CA: 126(22)287718u JOURNAL
In vivo gene therapy of murine melanoma mediated by recombinant vaccinia virus encoding human IL-2 gene
AUTHOR(S): Wan, Tao; Cao, Xuetao; Ju, Dian Wen; Aces, Bruce
LOCATION: Department of Immunology, Second Military Medical University, Shanghai, Peop. Rep. China, 200433
JOURNAL: Int. J. Oncol. DATE: 1997 VOLUME: 10 NUMBER: 4 PAGES: 703-708 CODEN: IJONES ISSN: 1019-6439 LANGUAGE: English PUBLISHER: International Journal of Oncology

16/3/44 (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126030339 CA: 126(3)30339e PATENT
Malaria peptides and vaccines
INVENTOR(AUTHOR): Baruch, Dror I.; Pasloske, Brittan L.; Howard, Russell J.

LOCATION: Neth.
ASSIGNEE: Affymax Technologies N.V.; Baruch, Dror I.; Pasloske, Brittan L.; Howard, Russell J.
PATENT: PCT International ; WO 9633736 A1 DATE: 19961031
APPLICATION: WO 96US5798 (19960426) *US 430908 (19950427)
PAGES: 144 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/015A; C12P-021/02B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES ; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN

16/3/45 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

125112293 CA: 125(9)112293d JOURNAL
Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus
AUTHOR(S): Zaitseva, Marina; Golding, Hana; Manischweitz, Jody; Webb, Deborah; Golding, Basil
LOCATION: Lab. Retrovirus Res., U.S. Food and Drug Administration, Bethesda, MD, 20892, USA
JOURNAL: Infect. Immun. DATE: 1996 VOLUME: 64 NUMBER: 8 PAGES: 3109-3117 CODEN: INFIBR ISSN: 0019-9567 LANGUAGE: English

16/3/46 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

125056212 CA: 125(5)56212n PATENT
Composition comprising a recombinant virus expressing an antigen and an immunostimulant, especially recombinant vaccinia virus, and use for vaccine or treatment of cancer or pathogen-caused diseases
INVENTOR(AUTHOR): Schlom, Jeffrey; Kantor, Judith
LOCATION: USA
ASSIGNEE: United States Dept. of Health and Human Services
PATENT: PCT International ; WO 9610419 A2 DATE: 960411
APPLICATION: WO 95US12624 (951002) *US 317268 (941003) *US 483316 (950607)
PAGES: 71 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A; A61K-045/05B DESIGNATED COUNTRIES: AM; AT; AU; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM DESIGNATED REGIONAL: KE; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FR ; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

16/3/47 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

120131745 CA: 120(11)131745r JOURNAL
Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
AUTHOR(S): Guo, Yajun; Wu, Mengchao; Chen, Hen; Wang, Xiaoning; Liu, Guangluo; Li, Guanglo; Ma, Jing; Sy, Man Sun
LOCATION: Tumor Immunol. Biother. Cent., East. Inst. Hepatobiliary Surg., Shanghai, Peop. Rep. China, 200433

JOURNAL: Science (Washington, D. C., 1883-) DATE: 1994 VOLUME: 263
NUMBER: 5146 PAGES: 518-20 CODEN: SCIEAS ISSN: 0036-8075 LANGUAGE:
English

4.

```
                                    bbb                 lll
                                     bb                  ll
pp ppp    ggg gg  aaaa    mm  mm    bb       eeee       ll
 pp  pp gg  gg       aa  mmmmmmmm  bbbbb  ee  ee      ll
 pp  pp gg  gg    aaaaa  mmmmmmmm  bb  bb eeeeee      ll
 ppppp   ggggg  aa  aa   mm m mm  bb  bb ee           ll
 pp         gg   aaa aa mm    mm bb bbb   eeee      llll
pppp    ggggg
```

```
  11      9999      11
 111     99  99    111
  11     99  99     11
  11      99999     11
  11         99     11
  11        99      11
111111    999    111111
```

7/18/01

Set	Items	Description
S1	21	E1-E4
S2	21	RD S1 (unique items)
S3	49	ICAM? AND CANDIDA
S4	25	RD S3 (unique items)
S5	6	ICAM? (20N) (VACCIN? OR ADJUVANT? OR IMMUNO?) AND CANDIDA
S6	0	RD S5
S7	4	RD S5 (unique items)
S8	1	ICAM? (20N) (VACCIN? OR ADJUVANT?) AND CANDIDA
S9	111	ICAM?(20N)(ADJUVANT? OR VACCIN?)
S10	60	RD S9 (unique items)
S11	1	S10 AND CANDIDA
S12	1	S11 AND (PATHOGEN? OR FUNGAL OR FUNGUS)
S13	22	S9 AND (PATHOGEN? OR FUNGAL OR FUNGUS)
S14	16	RD S13 (unique items)
S15	85	ICAM?(20N)(VACCIN?)

4.

```
                                    bbb                lll
                                     bb                 ll
pp ppp    ggg gg   aaaa    mm  mm    bb       eeee      ll
 pp  pp gg  gg       aa  mmmmmmmm  bbbbb  ee  ee     ll
 pp  pp gg  gg    aaaaa  mmmmmmmm  bb  bb eeeeee     ll
 ppppp   ggggg   aa  aa  mm m mm  bb  bb ee          ll
 pp         gg    aaa aa mm    mm bb bbb   eeee     llll
pppp    ggggg
```

```
  11      9999     8888
 111     99  99   88  88
  11     99  99   88  88
  11      99999    8888
  11         99   88  88
  11        99    88  88
111111    999      8888
```

7/18/01

20/7/18 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10782051 20432267 PMID: 10975799
DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13.
Soilleux EJ; Barten R; Trowsdale J
Immunology, Department of Pathology, Cambridge University, United Kingdom. ejs17@mole.bio.cam.ac.uk
Journal of immunology (UNITED STATES) Sep 15 2000, 165 (6) p2937-42, ISSN 0022-1767 Journal Code: IFB
Languages: ENGLISH
Document type: Journal Article
Record type: Completed
DC-SIGN is a C-type lectin, expressed on a dendritic cell subset. It is able to bind **ICAM3** and HIV gp120 in a calcium-dependent manner. Here we report the genomic organization of DC-SIGN and map it to chromosome 19p13 adjacent to the C-type lectin CD23 (FcepsilonRII). We also report a novel, closely linked gene, DC-SIGNR, which shows 73% identity to DC-SIGN at the nucleic acid level and a similar genomic organization. Proteins encoded by both genes have tracts of repeats of 23 aa, predicted to form a coiled coil neck region. They also possess motifs that are known to bind **mannose** in a calcium-dependent fashion. We show concomitant expression of the two genes in endometrium, placenta, and stimulated KG1a cells (phenotypically similar to monocyte-derived dendritic cells). The existence of a DC-SIGN-related gene calls for reinterpretation of the HIV data to consider possible DC-SIGN/DC-SIGNR hetero-oligomerization.

4

```
                                    bbb                 lll
                                     bb                  ll
pp ppp   ggg gg  aaaa   mm  mm     bb       eeee        ll
 pp  pp gg  gg      aa  mmmmmmm   bbbbb  ee  ee       ll
 pp  pp gg  gg   aaaaa  mmmmmmm   bb  bb eeeeee       ll
 ppppp   ggggg  aa  aa  mm m mm   bb  bb ee           ll
 pp         gg   aaa aa mm   mm bb bbb   eeee       llll
pppp    ggggg
```

```
 2222    00000   00000
22  22  00   00 00   00
    22  00  000 00  000
  222   00 0000 00 0000
 22     0000 00 0000 00
22  22  000  00 000  00
222222   00000   00000
```

7/18/01

07343027 BIOSIS NO.: 000090122929
CHARACTERIZATION OF HIGH ENDOTHELIAL-LIKE PROPERTIES OF PERITUBULAR CAPILLARY ENDOTHELIUM DURING ACUTE RENAL ALLOGRAFT REJECTION
AUTHOR: RENKONEN R; TURUNEN J P; RAPOLA J; HAYRY P
AUTHOR ADDRESS: TRANSPLANTATION LAB., UNIVERSITY HELSINKI, HAARTMANINKATU 3A, SF-00290 HELSINKI, FINLAND.
JOURNAL: AM J PATHOL 137 (3). 1990. 643-652. 1990
FULL JOURNAL NAME: American Journal of Pathology
CODEN: AJPAA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Acute allograft rejection is characterized by leukocyte infiltration. Previously we suggested that the site of entry of lymphocytes into rejecting kidney allografts is the peritubular but not other capillary enothelium. Here we confirm this observation in a frozen section ex vivo binding assay and further characterize the peritubular capillary endothelium during acute kidney allograft rejection. The increase in lymphocyte binding to peritubular capillaries precedes the peak of inflammation (leukocyte accumulation) in the graft. Pretreatment of lymphocytes with antibodies against CD 11a and CD 18 (LFA-1 .alpha. and .beta. chain, respectively) could decrease the lymphocyte binding, whereas **ICAM**-I pretreatment of tissue sections was ineffective. Light- and electron microscopy revealed a marked activation of peritubular capillary endothelial cells in allografts, whereas these alterations were less severe or absent in syngeneic controls and normal kidneys. Finally our data suggest that the ligand responsible for the binding of lymphocytes to kidney peritubular areas is organ specific. Only **mannose**-1 phosphate, but not **mannose**-6 phosphate, could decrease the lymphocyte binding. Y-1, an antibody staining rat lymph node high endothelial venules (HEV), did not react with allograft peritubular

4

```
                                    bbb                lll
                                     bb                 ll
pp ppp    ggg gg  aaaa    mm  mm    bb       eeee      ll
 pp  pp gg  gg       aa  mmmmmmmm  bbbbb  ee  ee     ll
 pp  pp gg  gg    aaaaa  mmmmmmmm  bb  bb eeeeee     ll
 ppppp   ggggg  aa  aa   mm m mm   bb  bb ee         ll
 pp         gg   aaa aa mm    mm bb bbb   eeee     llll
pppp    ggggg
```

```
 2222    00000   3333
22  22  00   00 33  33
    22  00  000     33
  222   00 0000   333
 22     0000 00     33
22  22  000  00 33  33
222222   00000   3333
```

7/18/01

08773180 BIOSIS NO.: 199395062531
Role of target cell glycoproteins in sensitivity to natural killer cell lysis.
AUTHOR: Ahrens Patricia B
AUTHOR ADDRESS: Dep. Biochem., Med. Coll. Wisconsin, 8701 Watertown Plank Rd., Milwaukee, Wis. 53226**
JOURNAL: Journal of Biological Chemistry 268 (1):p385-391 1993
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Natural killer cells select targets for lysis based on target cell glycoproteins. Compared to controls, K-562 cells treated with kifunensine, an inhibitor of Golgi mannosidase I, accumulate more high **mannose**-type asparagine-linked oligosaccharide, Man-9GlcNAc-2, and bind more concanavalin A, an oligomannosyl binding lectin. In addition, natural killer cell lysis of kifunensine-treated cells increases 34% over that of controls. Increased sensitivity to lysis occurs after treatment with other N-glycan processing inhibitors that promote accumulation of high **mannose**-type glycosides (deoxymannojirimycin and swainsonine). In addition, kifunensine-treated cells form more effector:target conjugates. Monoclonal antibodies to the adhesion molecule LFA-1 and its ligand **ICAM**-1 reduce lysis of control targets but are less effective in blocking lysis of kifunensine-treated cells. K-562 cells bind anti-**ICAM**-1 but not anti-LFA-1, and this binding does not change after kifunensine treatment. These data demonstrate conclusively a role for asparagine-linked oligosaccharides in the human natural killer cell:target interaction. The presence of high **mannose**-type glycans on K-562 cells correlates with increased binding of effectors and a greater susceptibility to lysis. These results support the idea that target cell N-glycosides influence the NK-target interaction mediated by adhesion molecules such as **ICAM**-1.

08838082 BIOSIS NO.: 199395127433
High **mannose** type N-linked oligosaccharides on endothelial cells may influence beta-2 integrin mediated neutrophil adherence in vitro.
AUTHOR: Sriramarao P(a); Berger Elaine; Chambers J David; Arfors Karl-E; Gehlsen Kurt R
AUTHOR ADDRESS: (a)La Jolla Inst. Exp. Med., 11077 North Torrey Pines Rd., La Jolla, CA 92037**USA
JOURNAL: Journal of Cellular Biochemistry 51 (3):p360-368 1993
ISSN: 0730-2312
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We report herein on the role of N-linked oligosaccharide processing of endothelial cell surface protein on the adhesion of neutrophils. Monolayers of human umbilical vein endothelial cells were treated for 24 h with deoxymannojirimycin (DMJ), an inhibitor of golgi mannosidase I, which results in changes in glycoprotein processing, and then incubated with neutrophils to examine their ability to adhere to the treated endothelial cells. Treatment with DMJ, which leads to accumulation of high **mannose** type oligosaccharides, resulted in a twofold increase in adherence of phorbol ester(PMA) activated neutrophils compared to attachment to untreated endothelial cells. This adherence was likely mediated by the beta-2 subunit. Similarly, IL-1 treatment resulted in a beta-2 integrin mediated increase in neutrophil adherence to the DMJ treated endothelial cells in a dose dependent manner. However, the IL-1 induced adherence was not significantly inhibited by the anti-**ICAM** -1 antibody, thus, suggesting the presence of other inducible components on the endothelial cell surface. Our results demonstrate that alterations in glycosylation of N-linked oligosaccharides, resulting in the synthesis of high **mannose** type sugars on molecules that may interact with the beta-2 integrins, leads to an increased adherence of PMA activated neutrophils to endothelial cells.

4

```
                                    bbb                 lll
                                     bb                  ll
pp ppp    ggg gg  aaaa    mm  mm    bb       eeee       ll
 pp  pp gg  gg       aa  mmmmmmmm  bbbbb  ee  ee      ll
 pp  pp gg  gg    aaaaa  mmmmmmmm  bb  bb eeeeee      ll
 ppppp   ggggg  aa  aa  mm m mm  bb  bb ee            ll
 pp         gg   aaa aa mm    mm bb bbb   eeee      llll
pppp    ggggg
```

```
 2222    00000  777777
22  22  00   00 77  77
    22  00  000     77
  222   00 0000    77
 22     0000 00   77
22  22  000  00   77
222222   00000    77
```

7/18/01

41331 BIOSIS NO.: 199698696249
Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
AUTHOR: Thornton Brian P; Vetvicka Vaclav; Pitman Mark; Goldman Robert C; Ross Gordon D(a)
AUTHOR ADDRESS: (a)Div. Experimental Immunol. Immunopathol., Dep. Pathol., Univ. Louisville, Louisville, KY 40292**USA
JOURNAL: Journal of Immunology 156 (3):p1235-1246 1996
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Zymosan, the cell wall from Saccharomyces cerevisiae, was reported to be a macrophage activator through its beta-glucan over 30 yr ago. Nevertheless, the identity of the beta-glucan receptor has been controversial. This study showed that the alpha-M-beta-2-integrin, CR3 (Mac-1, CD11b/CD18) served as the beta-glucan receptor through one or more lectin sites located outside of the CD11b 1-domain that contains the binding sites for iC3b, **ICAM**-1, and fibrinogen. Sugar specificity, analyzed with FITC-labeled soluble polysaccharides and flow cytometry, showed CR3-specific staining with several pure beta-glucans but not with alpha-mannan. However, a 10-kDa soluble zymosan polysaccharide (SZP) with high affinity (6.7 times 10-8 M) for CR3 consisted largely of **mannose** and apprx 5% glucose. Binding of either SZP-FITC or beta-glucan-FITC to CR3 was blocked not only by pure beta-glucans from yeast, mushroom, seaweed, or barley, but also by N-acetyl-D-glucosamine (NADG), alpha- or beta-methylmannoside, and alpha- or beta-methylglucoside. SZP-FITC and beta-glucan-FITC stained all leukocyte types similarly, to anti-CR3-FITC, and polysaccharide-FITC staining was inhibited gtoreq 95% by unlabeled anti-CR3. SZP-FITC staining of cells expressing recombinant chimeras between CR3 and CR4 (p150,95, CD11c/CD18) suggested that both the divalent cation-binding region of CD11b and the region C-terminal to it may regulate binding of polysaccharides to CR3. Unlabeled SZP or beta-glucan also blocked CR3 staining by 11 mAb to C-terminal domain epitopes of CD11b but had no effect on staining by mAb directed to the 1-domain. In conclusion, CR3 serves as the leukocyte beta-glucan receptor through a cation-independent lectin site located C-terminal to the I-domain of CD11b. Its sugar specificity is broader than originally appreciated, allowing it to react with certain polysaccharides containing **mannose** or NADG, as well as glucose.

5/KWIC/53 (Item 8 from file: 73)

...the immunoglobulin superfamily. The interaction between ICAM-1 on B lymphocytes and leukocyte function-associated **antigen** 1 on T cells plays a major role in several aspects of the immune response, including T-dependent B cell activation. While it was originally believed that **ICAM-1** played a purely adhesive role, recent evidence suggests that it can itself transduce biochemical signals. We demonstrate that cross-**linking** of **ICAM-1** results in the up-regulation of class II major histocompatibility complex, and we investigate the biochemical mechanism for the signaling role of **ICAM-1**. We show that cross-**linking** of **ICAM-1** on the B lymphoma line A20

3/3/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

101070703 CA: 101(9)70703j JOURNAL
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies
AUTHOR(S): Perussia, Bice; Trinchieri, Giorgio; Jackson, Ann; Warner, Noel L.; Faust, Jeffrey; Rumpold, Helmut; Kraft, Dietrich; Lanier, Lewis L.
LOCATION: Wistar Inst. Anat. Biol., Philadelphia, PA, 19104, USA
JOURNAL: J. Immunol. DATE: 1984 VOLUME: 133 NUMBER: 1 PAGES: 180-9
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English

3/3/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

101052885 CA: 101(7)52885r JOURNAL
Biology of disease. Human natural killer cells: biologic and pathologic aspects
AUTHOR(S): Trinchieri, Giorgio; Perussia, Bice
LOCATION: Wistar Inst. Anat. Biol., Philadelphia, PA, USA
JOURNAL: Lab. Invest. DATE: 1984 VOLUME: 50 NUMBER: 5 PAGES: 489-513
CODEN: LAINAW ISSN: 0023-6837 LANGUAGE: English

3/3/5 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

100137118 CA: 100(17)137118x JOURNAL
Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells
AUTHOR(S): Perussia, Bice; Trinchieri, Giorgio
LOCATION: Wistar Inst. Anat. Biol., Philadelphia, PA, 19104, USA
JOURNAL: J. Immunol. DATE: 1984 VOLUME: 132 NUMBER: 3 PAGES: 1410-15
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English

2/KWIC/47 (Item 47 from file: 654)

...or intraperitoneal (i.p.) injections of the CD11a or CD18 polypeptide or dimer thereof or **ICAM-1**, together with an adjuvant. It may be useful to **conjugate** the LFA-1 or **ICAM-1 antigen** polypeptide (including its chains and fragments containing the target amino acid sequence) to a protein that is **immunogenic** in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (**conjugation** through cysteine residues), N-hydroxysuccinimide (through

2/KWIC/28 (Item 28 from file: 654)
DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

... according to claim 2 wherein the T lymphocytes are MHC class I restricted.

9. The **composition** according to claim 6 wherein the cancer antigen peptide or **antigenic** epitope thereof comprises the sequence of SEQ ID No: 7.

10. The **composition** according to claim 6 further comprising an immunostimulatory molecule selected from the group consisting of an MHC class I molecule, an MHC class II molecule, B7.1, B7.2, **ICAM-1**, ICAM-2, LFA-1, LFA-3, CD72, an interleukin, TNF alpha, IFN gamma, RANTES, G ... said variant having the biological function of stimulating cancer antigen specific T lymphocytes.

14. A **composition** comprising the cancer antigen peptide or antigenic epitope thereof according to claim 13 and a pharmaceutically acceptable carrier.

15. An immunogen comprising the cancer peptide or **antigenic** epitope thereof according to claim 13.

16. The **composition** according to claim 14 further comprising an immunostimulatory molecule selected from the group consisting of an MHC class I molecule, an MHC class II molecule, B7.1, B7.2, **ICAM-1**, ICAM-2, LFA-1, LFA-3, CD72, an interleukin, TNF alpha, IFN gamma, RANTES, G ...

...the amino acid sequence:
MSLQRQFLR (SEQ ID NO: 9) or antigenic portion thereof.

18. A **composition** comprising the cancer peptide or antigenic epitope thereof according to claim 17 and a pharmaceutically acceptable carrier.

19. An immunogen comprising the cancer **antigen** peptide or **antigenic** epitope thereof according to claim 17.

20. The **composition** according to claim 18 further comprising an immunostimulatory molecule selected from the group consisting of an MHC class I molecule, an MHC class II molecule, B7.1, B7.2, **ICAM-1**, ICAM-2, LFA-1, LFA-3, CD72, an interleukin, TNF alpha, IFN gamma, RANTES, G ...

2/KWIC/29 (Item 29 from file: 654)
DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

OTHER REFERENCES

...2978 (Dec. 1984).

Krensky, A.M. et al., LFA-1, LFA-2 and LFA-3 **Antigens** Are Involved in CTL-Target **Conjugation**, J. Immunol. 132(5):2180-2182 (May 1984).

Makgoba, M.W. et al., Functional Evidence that intercellular adhesion molecule-1 (**ICAM-1**) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity, Eur. J...

... reactions. This potential therapeutic use may be exploited in either of two manners. First, a **composition** containing a monoclonal antibody against **ICAM-1** may be administered to a patient experiencing delayed type hypersensitivity reaction. For example, such **compositions** might be provided to a individual who had been in contact with **antigens** such as poison ivy, poison oak, etc. In the second embodiment, the monoclonal antibody capable of binding to **ICAM -1** is administered to a patient in conjunction with an **antigen** in order to prevent a subsequent inflammatory reaction. Thus, the additional administration of an **antigen** with an **ICAM-1** -binding monoclonal antibody may temporarily tolerize an individual to subsequent presentation of that **antigen**.

3. Therapy for Chronic Inflammatory Disease

Since LAD patients that lack LFA-1 do not mount an inflammatory response, it is believed that antagonism of LFA-1's natural ligand, **ICAM-1** , will also inhibit an inflammatory response. The ability of antibodies against ICAM-1 to inhibit...

2/KWIC/16 (Item 16 from file: 654)
DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

...beta by said leukocyte cell.

11. The kit of claim 6, wherein said second pharmaceutical **composition** comprises a binding ligand that comprises a first binding region that binds to the cytokine-inducible marker VCAM-1, E-selectin, endoglin, **ICAM-1** or an MHC Class II **antigen**.

12. The kit of claim 6, wherein said first pharmaceutical **composition** comprises a bispecific antibody that binds to the activating **antigen** CD14 and induces the expression of IL-1 by monocyte/macrophage cells.

13. The kit of claim 12, wherein said first pharmaceutical **composition** comprises a bispecific antibody that binds to the activating antigen CD14 and to the tumor...a coagulation factor.

48. The kit of claim 47, wherein said first or second pharmaceutical **compositions** comprise an antibody comprising a first binding region that binds to VCAM-1, E-selectin, endoglin, **ICAM-1**, an MHC Class II **antigen**, VEGF or FGF.

49. The kit of claim 47, wherein said first pharmaceutical **composition** comprises an anti-VEGF-Tissue Factor antibody; and wherein said second pharmaceutical **composition** comprises an anti-VCAM-1-Tissue Factor antibody or an anti-E-selectin-Tissue Factor... beta by said leukocyte cell.

60. The method of claim 55, wherein said second pharmaceutical **composition** comprises a binding ligand that comprises a first binding region that binds to the cytokine-inducible marker VCAM-1, E-selectin, endoglin, **ICAM-1** or an MHC Class II **antigen**.

61. The method of claim 55, wherein said first pharmaceutical **composition** comprises a bispecific antibody that binds to the activating **antigen** CD14 and induces the expression of IL-1 by monocyte/macrophage cells.

62. The method of claim 61, wherein said first pharmaceutical **composition** comprises a bispecific antibody that binds to the activating antigen CD14 and to the tumor...

2/KWIC/17 (Item 17 from file: 654)
DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

... promoters containing those promoter motifs, cDNAs that encode such molecules, and related therapeutic and diagnostic **compositions** and methods. A specific embodiment of the present invention relates to TSU genes, their encoded...

...as derivatives, analogs, and fragments thereof, that suppress expression of MHC class I and II **antigens** and **ICAM-1**, B7-1, B7-2 and Fc gamma R **antigens**. The invention further relates to methods of therapy and diagnosis and therapeutic **compositions** using TSU nucleic acids to suppress MHC class I and II **antigen** and **ICAM-1**, B7-1, B7-2 and Fc gamma R **antigen** expression.

2. BACKGROUND OF THE INVENTION

Control of gene expression underlies, at some level, all...

2/KWIC/18 (Item 18 from file: 654)

... format to detect the presence or absence of arginine at amino acid residue 241 of **ICAM-1** . "ELISA" refers to an enzyme-linked immunosorbent assay that employs an antibody or **antigen** immobilized on solid matrix and an enzyme-**antigen** or enzyme-antibody **conjugate** to detect and quantify the amount of an **antigen** present in a sample. A description of the ELISA technique is found in Chapter 22... the present invention can be used in mammalian therapeutic methods, preferably human, as a R241 **ICAM-1** agonist or to neutralize or modulate the effect of R241 **ICAM-1**.

"Antibody" also encompasses fragments, like Fab and F(ab')2, of anti-R241 **ICAM-1** antibodies, and **conjugates** of such fragments, and so-called "**antigen** binding proteins" (single-chain antibodies) which are based on anti-R241 **ICAM-1** antibodies, in accordance, for example, with U.S. Pat. No. 4, 704,692, incorporated herein by reference.

Antibodies against **ICAM-1** encoded by the R241 allele can also be employed in the generation, via conventional methodology...or inhibiting either transcription [type (a)] or translation [type (b)].

The present invention contemplates therapeutic **compositions** useful for practicing the therapeutic methods described herein. Therapeutic **compositions** of the present invention may contain a physiologically tolerable carrier together with a ICAM-I antisense oligonucleotide or anti-**ICAM-1** antibody, as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic **composition** is not **immunogenic** when administered to a mammal or human patient for therapeutic purposes. To some extent this...

2/3/47 (Item 47 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02640573
Utility
METHOD FOR TREATING A LFA-1-MEDIATED DISORDER
[Administering initial dosage of antibody, subsequent intermittent dosing]

PATENT NO.: 5,622,700
ISSUED: April 22, 1997 (19970422)
INVENTOR(s): Jardieu, Paula M., Berkeley, CA (California), US (United States of America)
Montgomery, Bruce, Redwood City, CA (California), US (United States of America)
ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]
APPL. NO.: 8-432,543
FILED: May 02, 1995 (19950502)

CROSS REFERENCE

This application is a continuation of co-pending U.S. application Ser. No. 08-287,055 filed 8 Aug. 1994, pending, which application is a continuation of U.S. application Ser. No. 08-128,329 filed 28 Sep. 1993 (abandoned), which application is a continuation of U.S. application Ser. No. 07-933,269 filed 21 Aug. 1992 (abandoned), which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC selection 120.

FULL TEXT: 1599 lines

2/3/57 (Item 57 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02236929
Utility
SELECTIVE INHIBITION OF GENE EXPRESSION BY PHOTOACTIVATABLE OLIGONUCLEOTIDES
[Administering to cell containing targeted DNA a photoactivat-able ultraviolet radiation product of a compound containing two photoactivatable functional groups and an oligonucleotide]

PATENT NO.: 5,256,648
ISSUED: October 26, 1993 (19931026)
INVENTOR(s): Gasparro, Francis P., Hamden, CT (Connecticut), US (United States of America)
Edelson, Richard L., Westport, CT (Connecticut), US (United States of America)
ASSIGNEE(s): Yale University, (A U.S. Company or Corporation), New Haven, CT (Connecticut), US (United States of America)
[Assignee Code(s): 1311]
EXTRA INFO: Expired, effective October 29, 1997 (19971029), recorded in O.G. of January 6, 1998 (19980106)
APPL. NO.: 7-410,622

FILED: September 21, 1989 (19890921)
APPLICATIONS

This application is a continuation-in-part application of copending U.S. application Ser. No. 299,265 filed Jan. 23, 1989, abandoned, which is a continuation-in-part of copending U.S. application Ser. No. 146,571 filed Jan. 21, 1988, abandoned.

FULL TEXT: 1011 lines

2/3/58 (Item 58 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02076124
Utility
MODIFIED PF4 COMPOSITIONS AND METHODS OF USE
[Polypeptides and proteins with mutant segments for treatment of cardiovascular disorders and antitumor agents]

PATENT NO.: 5,112,946
ISSUED: May 12, 1992 (19920512)
INVENTOR(s): Maione, Theodore, Wakefield, MA (Massachusettes), US (United States of America)
ASSIGNEE(s): Repligen Corporation, (A U.S. Company or Corporation), Cambridge, MA (Massachusettes), US (United States of America) [Assignee Code(s): 10790]
EXTRA INFO: Expired, effective May 12, 2000 (20000512), recorded in O.G. of July 25, 2000 (20000725)
APPL. NO.: 7-376,333
FILED: July 06, 1989 (19890706)
FULL TEXT: 681 lines

3/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: administration of recombinant fowlpox vector expressing CEA and three different costimulatory molecule transgenes (B7-1, **ICAM-1**, LFA-3, designated rF-CEA/TRICOM) was more potent in inducing CEA-specific T-cell responses than four **vaccinations** with rF-CEA or two **vaccinations** with rF-CEA/B7-1. Moreover, up to four **vaccinations** with rF-CEA/TRICOM induced greater CEA-specific T-cell responses with each **vaccination**. (b) A diversified prime and boost strategy using a prime with a recombinant vaccinia vector...

3/KWIC/10 (Item 10 from file: 5)
DIALOG(R)File 5:(c) 2001 BIOSIS. All rts. reserv.

...ABSTRACT: a T cell has been shown to require two signals via molecules present on professional **antigen**-presenting cells: signal 1, via a peptide/MHC complex; and signal 2, via a costimulatory...

...the role of three costimulatory molecules in the activation of T cells was examined. Poxvirus (**vaccinia** and avipox) vectors were used because of their ability to efficiently express multiple genes. Murine cells provided with signal 1 and infected with either recombinant **vaccinia** or avipox vectors containing a TRIad of COstimulatory Molecules (B7-1/**ICAM-1**/LFA-3, designated TRICOM) induced the

02922387

Utility

MODULATORS OF THE INTERACTION BETWEEN ICAM-R AND .ALPHA..SUB.D /CD18

[Monoclonal antibodies and fragments, single chain antibodies, chimeric antibodies and complementary determining region grafted antibodies having binding affinity for intercellular adhesion molecule R; asthma therapy, HIV, viricides;]

PATENT NO.: 5,880,268
ISSUED: March 09, 1999 (19990309)
INVENTOR(s): Gallatin, W. Michael, Seattle, WA (Washington), US (United States of America)
Vazeux, Rosemay, Seattle, WA (Washington), US (United States of America)
ASSIGNEE(s): ICOS Corporation, (A U.S. Company or Corporation), Bothell, WA (Washington), US (United States of America)
[Assignee Code(s): 36677]
APPL. NO.: 8-483,932
FILED: June 07, 1995 (19950607)

This is a Divisional of U.S. application Ser. No. 08-286,754, filed Aug. 5, 1994 now abandoned which in turn is a Continuation-in-Part of U.S. application Ser. No. 08-102,852, filed Aug. 5, 1993 now abandoned, which in turn is a Continuation-in-Part of U.S. application Ser. No. 08-009,266, filed Jan. 22, 1993 now abandoned, and a Continuation-in-Part of PCT-US93-00787, filed Jan. 26, 1993 which in turn is a Continuation-in-Part of U.S. application Ser. No. 07-894,061, filed Jun. 5, 1992 now abandoned, which in turn is a Continuation-in-Part of U.S. application Ser. No. 07-889,724, filed May 26, 1992 now abandoned, which in turn is a Continuation-in-Part of U.S. application Ser. No. 07-827,689, filed Jan. 27, 1992 now abandoned.

FULL TEXT: 6120 lines

(Item 26 from file: 654)

OTHER REFERENCES

... et al., "Structure and Regulation of the Leukocyte Adhesion Receptor LFA-1 and Its Counterreceptors, **ICAM**-1 and **ICAM**-2", CSH Symp. Qual., 54:753-765 (1989).

Dustin et al., "T-Cell Receptor Cross-Linking Transiently **Stimulated** Adhesiveness Through LFA-1", Nature, 341:619-624 (1989).

Edwards, "Cell Adhesion Molecules as a...

... depicting the results of in situ hybridizations of transfected L cells using ICAM-R or **ICAM**-1 RNA probes;

FIG. 4A comprises bar graphs illustrating the results of assays for the adhesion of PMA-**stimulated** or unstimulated lymphoblastoid cells from patients with leukocyte adhesion deficiency to soluble **ICAM**-R in the presence and absence of anti-CD18 antibody, while FIG. 4B comprises bar graphs illustrating the results of assays for the adhesion of various other PMA-**stimulated** or unstimulated cell lines to soluble **ICAM**-R in the presence and absence of anti-CD18 or anti-CD11a ...A through G) presents photomicrographs of immunohistologic staining of various human tissues with an anti-**ICAM**-R monoclonal antibody;

FIG. 10 is a bar graph depicting the effects of anti-**ICAM**-R monoclonal antibodies on the **stimulation** of lymphocyte proliferation by anti-CD3 antibodies;

FIG. 11(A through B) comprises bar graphs illustrating the effects of anti-**ICAM** -R monoclonal antibodies on superantigen-induced proliferation of human peripheral blood lymphocytes, while FIG. 11C...
... published Jan. 29, 1992, for example, addresses the development of multimeric configurations and forms of **ICAM**-1 (including full length and truncated molecular forms) proposed to have **enhanced** ligand/receptor binding activity, especially in binding to viruses, lymphocyte associated antigens and **pathogens** such as Plasmodium falciparum.

In a like manner, a variety of uses have been projected...of the specified amino acids is deleted or replaced: (1) without loss, and preferably with **enhancement**, of one or more biological activities or immunological characteristics specific for **ICAM** -R; or (2) with specific disablement of a particular ligand/receptor binding function. Analog polypeptides...on their surfaces. They are also manifestly useful in modulating (i.e., blocking, inhibiting or **stimulating**) ligand/receptor binding biological activities involving **ICAM** -R, especially those **ICAM**-R effector functions involved in specific and non-specific immune system responses. Anti-idiotypic antibodies... is manifest. As one series of examples, knowledge of the sequence of a cDNA for **ICAM** -R makes possible the isolation by DNA/DNA hybridization of genomic DNA sequences encoding ICAM...

... stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of **ICAM**-R, other structurally related proteins sharing one or more of the biological and/or immunological properties specific to **ICAM**-R, and non-human species (e.g., rodent) proteins homologous to **ICAM**-R. DNAs of the invention are useful in

DNA/RNA hybridization assays to detect the capacity of cells to synthesize **ICAM**-R. Also made available by the invention are anti-sense polynucleotides relevant to regulating expression of **ICAM**-R by those cells which ordinarily express the same. As another series of examples, knowledge of the DNA and amino acid sequences of **ICAM**-R makes possible the generation by recombinant means of **ICAM**-R variants such as hybrid **fusion proteins** (sometimes referred to as "immunoadhesions") characterized by the presence of **ICAM**-R **protein** sequences and immunoglobulin heavy chain constant regions and/or hinge regions. See, Capon et al...

...S. (USA), 88: 10535-10539 (1991); and PCT WO 89/02922, published Apr. 6, 1989. **ICAM**-R variant **fusion proteins** may also include, for example, selected extracellular domains of **ICAM**-R and portions of other cell adhesion molecules.

The DNA and amino acid sequence information...beneficially by ICAM-R related products of the invention described herein. The therapeutic use of **ICAM**-R analogs incorporating specific amino acid substitutions (e.g., analogs E37T or D231H) chosen to **enhance** or diminish their specific immunomodulatory properties are useful in this regard. Specific examples of T cell dependent diseases for which **ICAM**-R related products may have utility include but are not limited to asthma, psoriasis, diabetes... ... were then washed with RPMI-FCS and scanned with an automatic fluorescence reader.

Adhesion of **stimulated** SKW3 cells to both the **ICAM**-R and the **ICAM** -1 transfectants was inhibited by monoclonal antibodies against either the alpha (CD11a) or beta (CD18...injections of Macaca nemestrina spleen cells in 0.5 ml PBS containing 50 mu g **adjuvant** peptide on days 128 and 177. For fusion 56, mouse #845 was injected with 2.24 mu g soluble **ICAM**-R (Example 10) in 700 mu l PBS, 100 mu l was given i.v ...

...cells as described for fusion 56 and on day 248 with 50 mu g soluble **ICAM**-R in 100 mu l complete Freuds **adjuvant** given s.c. The mouse received a final boost i.v. of 66 mu g soluble **ICAM**-R in 100 mu l PBS. The spleen was removed sterilely four days later.

For...

...mouse received 40 mu g of shICAM-R in 0.2 ml incomplete Freund's **adjuvant**. On day 136 mouse #1264 (Fusion 81) was given a final ... was screened by ELISA on COS cells transiently transfected with either a domain 1 deleted **ICAM**-R construct [Example 14.C.1] or with an ICAM-2 ... for FACS analyses in Example 12C using either 0.1 ml hybridoma culture supernatant (anti-**ICAM**-R) or 1 mu g pure monoclonal antibody (anti-**ICAM**-1 or **ICAM**-2) per 5X10 sup 5 cells. Results of the analyses are presented as histograms (representing 10 sup 4 cells analyzed) in FIG. 5. Anti-**ICAM** -R antibodies specifically bound to L cells transfected with ICAM-R cDNA, but not toMolecule
Antibody
Protein 1
Protein 2
Protein 3
ICAM-R **ICAM**-1...in binding of the above nine monoclonal antibodies in comparison to binding to wild type **ICAM** -R. Mutation F21V/AS abolished binding of all antibodies and appears to grossly affect the...

... lines were respectively assayed by FACS analysis and Northern blot hybridization.

A. FACS Analyses of **ICAM**-R Protein Distribution In Leukocytic Cell Lines and Normal Leukocytes

FACS analyses carried out as described in Example 12C on leukocyte cell lines using anti-**ICAM**-R monoclonal antibody ICR-2.1, anti-**ICAM** -1 antibody (LB2) and anti-CD18 antibody (TS1/18, ATCC HB203) illustrated that **ICAM**-R is ...of the major leukocyte lineages: T lymphocytes, B lymphocytes, and myeloid cells. Surface expression of **ICAM**-R was not detected on the primitive erythroleukemic line, K562. Further, **ICAM**-R was not expressed detectably by cultured human umbilical vein endothelial cells (HUVECS) either before or after stimulation with tumor necrosis factor which did upregulate expression of **ICAM**-1. This pattern of expression is also distinct from that observed for **ICAM**-2 which is expressed on endothelium. Table 7 below provides the mean fluorescence of each... leukocytic cell types. ICAM-R RNA expression was not necessarily concomitant with the expression of **ICAM** -1 RNA. For example, unstimulated HUVECS express low levels of **ICAM**-1 and expression is upregulated following TNF **stimulation** (FIG. 7B). In contrast, detectable levels of **ICAM**-R message were not observed in unstimulated or **stimulated** HUVECS (FIG. 7A).

EXAMPLE 16

The expression of **ICAM** -R transcript in endothelial cells was examined. Poly A+ mRNA was obtained from human skin...
? s (icam(w)1)(20n)(vaccin? or adjuvant? or stimulat? or enhanc?) and (icam(w)1)(10n)(conjugat? or link? or fusion(w)protein?) and pathogen?

7/3/46 (Item 46 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

02514332
Utility
RAPID IMMUNOSELECTION CLONING METHOD
[Diagnosis, therapy antigen]

PATENT NO.: 5,506,126
ISSUED: April 09, 1996 (19960409)
INVENTOR(s): Seed, Brian, Boston, MA (Massachusettes), US (United States of America)
Aruffo, Alejandro, Edmonds, WA (Washington), US (United States of America)
ASSIGNEE(s): The General Hospital Corporation, (A U.S. Company or Corporation), Charlestown, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 10301]
APPL. NO.: 8-139,273
FILED: October 18, 1993 (19931018)

This application is a divisional of U.S. patent application Ser. No. 07-983,647, filed Dec. 1, 1992, which is a continuation-in-part of U.S. patent application Ser. No. 553,759, filed Jul. 13, 1990; now abandoned, which is a continuation-in-part of U.S. Ser. No. 379,076, filed Jul. 13, 1989; now abandoned, which is a continuation-in-part of U.S. Ser. No. 160,416, filed Feb. 25, 1988, now abandoned. Each of these predecessor applications and all references cited herein are incorporated by reference in their entirety.

7/KWIC/39 (Item 39 from file: 654)

OTHER REFERENCES

... al., "Treatment of Rheumatoid Arthritis Patients with a Monoclonal Antibody to Intercellular Adhesion Molecule-1 (**ICAM-1**) Results in T Lymphocyte Hyporesponsiveness to in vitro Mitogenic **Stimulation**" FASEB J. 8: A745 (1994).

Omura, T. et al., "Accerlerated Rejection of Allografted Rat Liver Perfused with Anti-**ICAM-1** Monoclonal Antibody" Immunobiol. 186: 241-245 (1992).

Kavanaugh, A.F. et al., "Anti-CD54 (Intercellular...

... Lung 170:267-279 (1992)) confirmed the contribution of leukocyte adhesion and infiltration in the **pathogenesis** of pulmonary oxygen toxicity in a mouse model, and reported that the administration of a...or equivalent strains. The animals are preferably immunized with approximately 25 mu g of human **ICAM-1** (or a fragment thereof) that has been emulsified a suitable **adjuvant** (e.g., Freund's **adjuvant** , TiterMax **adjuvant** (Vaxcel, Norcross, Ga.), etc.). Immunization may be conducted at two intramuscular sites, one intraperitoneal site... to poly(ethylene) glycol-modification.

Intercellular adhesion molecule-1 (ICAM-1) is involved in the **pathogenesis** of many inflammatory conditions. Modulation of cell adhesion through the interference with ICAM-1-dependent...binding site from PEG attachment. While both the column and solution methods produce mPEG-anti-**ICAM-1** antibody **conjugates** that retain binding activity, the column method permits more mPEG to be attached to the...

2/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09796826 BIOSIS NO.: 199598251744
Host defenses against **Candida** are impaired in **ICAM-1** deficient mice.
AUTHOR: Davis Susan L(a); Hawkins Edith P; Mason Edward O Jr; Smith C Wayne ; Kaplan Sheldon L
AUTHOR ADDRESS: (a)Dep. Pediatr., Baylor Coll. Med., Houston, TX**USA
JOURNAL: Pediatric Research 37 (4 PART 2):p173A 1994
CONFERENCE/MEETING: 105th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the Society for Pediatric Research San Diego, California, USA May 7-11, 1995
ISSN: 0031-3998
RECORD TYPE: Citation
LANGUAGE: English